Annual and Financial Report 2020
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual report</td>
<td>3</td>
</tr>
<tr>
<td>Preface</td>
<td>3</td>
</tr>
<tr>
<td>A few words from our Chairperson</td>
<td>3</td>
</tr>
<tr>
<td>A few words from the Chairperson of the European Working Group of People with Dementia</td>
<td>5</td>
</tr>
<tr>
<td>Executive Summary</td>
<td>6</td>
</tr>
<tr>
<td>Introduction</td>
<td>9</td>
</tr>
<tr>
<td>AE core activities</td>
<td>10</td>
</tr>
<tr>
<td>Objective 1: Providing a voice to people with dementia and their carers</td>
<td>10</td>
</tr>
<tr>
<td>Objective 2: Making dementia a European priority</td>
<td>11</td>
</tr>
<tr>
<td>Objective 3: Promoting a rights-based approach to dementia</td>
<td>13</td>
</tr>
<tr>
<td>Objective 4: Supporting dementia research</td>
<td>14</td>
</tr>
<tr>
<td>Objective 5: Strengthening the European dementia movement</td>
<td>16</td>
</tr>
<tr>
<td>Other activities and projects</td>
<td>18</td>
</tr>
<tr>
<td>Involvement in EU projects</td>
<td>18</td>
</tr>
<tr>
<td>Support of European research activities</td>
<td>24</td>
</tr>
<tr>
<td>Corporate affairs</td>
<td>26</td>
</tr>
<tr>
<td>Annex 1: 2020 Meetings</td>
<td>30</td>
</tr>
<tr>
<td>Meetings organised by AE in the framework of the 2020 Operating Grant</td>
<td>30</td>
</tr>
<tr>
<td>Meetings attended by Alzheimer Europe representatives in the framework of the 2020 Operating Grant</td>
<td>31</td>
</tr>
<tr>
<td>Other meetings organised by Alzheimer Europe or attended by Alzheimer Europe representatives in 2020</td>
<td>32</td>
</tr>
<tr>
<td>Financial Report</td>
<td>37</td>
</tr>
<tr>
<td>A few words from our Honorary Treasurer</td>
<td>37</td>
</tr>
<tr>
<td>Report of the Réviseur d'entreprises agréé</td>
<td>39</td>
</tr>
<tr>
<td>Breakdown of income</td>
<td>52</td>
</tr>
<tr>
<td>Our sponsors and supporters</td>
<td>54</td>
</tr>
<tr>
<td>Alzheimer Europe Board</td>
<td>55</td>
</tr>
<tr>
<td>Alzheimer Europe staff</td>
<td>56</td>
</tr>
</tbody>
</table>

This publication received funding under an operating grant from the European Union’s Health Programme (2014–2020). The content of this publication represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.
Preface

A few words from our Chairperson

As the Chairperson of Alzheimer Europe, it gives me great pleasure to introduce our 2020 Annual Report, looking back at our activities and achievements last year. As in the past, our core activities were funded by an operating grant awarded by the European Commission in the framework of the European Union’s health programme. I would like to express our gratitude for this ongoing support, which allows the organisation and its national member organisations to continue to give a voice to people with dementia, make dementia a public health priority, support dementia research and strengthen the European dementia movement, all the while ensuring that all these activities are firmly rooted in a rights-based approach.

Last year, with the onset of the global COVID-19 pandemic, we were all forced to adapt many aspects of our day-to-day lives and our work. Much more of Alzheimer Europe’s work and all of its meetings and events, from March 2020 onwards, were conducted online. Our staff and Board members worked from home for much of the time and continue to do so, as the pandemic continues to affect us all. I would like to thank everyone for making sure that our work continued to be done to the same high standard as always. It has been truly inspiring to see how committed and willing everyone has remained throughout this trying time, and I wish everyone to continue to stay safe, with the hope of meeting you all in person again, soon.

This online approach to our work has meant that some of our longer meetings / events were split into several shorter parts, which is more manageable for everyone involved. In 2020, Alzheimer Europe involved people living with dementia in all aspects of its work and the organisation’s European Working Group of People with Dementia (EWGPWD) held over 20 virtual meetings. At these meetings, the 14 group members provided input on several EU-funded research projects; prepared a special symposium (in video format), discussing the impact of COVID on people with dementia, for our virtual Annual Conference in October; and developed a set of recommendations on dementia-inclusive meetings, venues and travel. The group’s Chairperson also participated in all five of Alzheimer Europe’s Board meetings during 2020, as an ex-officio Board member with full voting rights. Our organisation benefits immensely from the invaluable input and example of this dedicated group of people living with dementia and I would like to commend them for their important advocacy and PI (Public involvement) work.

Policymakers, organisations and research bodies across Europe and the world worked tirelessly during 2020, to highlight the impact of COVID on people living with dementia and their carers, as well as to ensure a coordinated response to dementia, at national, European and international levels. As part of our own efforts to support people with dementia, carers, care professionals and national Alzheimer’s associations during the ongoing COVID-19 situation, we put together a range of valuable online resources with helpful information, tips and guidelines, as well as creating a special section in our newsletter for relevant updates about all aspects of COVID. We also adopted two policy positions during 2020, on triage decisions, on the wellbeing of people with dementia and carers, and on dementia research during COVID.

Also on the policy front, Alzheimer Europe welcomed news from Spain, where the country’s national dementia strategy was published (following its official launch in 2019); from Croatia, where the Parliament agreed that the country should work towards a strategy as soon as possible; and from Germany, Iceland, Netherlands and Norway, all of which launched new national dementia strategies during 2020. We were also delighted to learn that the Czech Republic would launch its new strategy in 2021 and to learn of the commitment from the Italian Government to provide funding for the country’s National Dementia Plan, which was first launched in 2014.

Alzheimer Europe convened three meetings of the European Group of Governmental Experts on Dementia attended by representatives from 25 health ministries and observers from the European Commission, the Organisation for Economic Cooperation and Development (OECD) and the World Health Organization (WHO). This group was conceived as a response to the decision of the European Commission to disband its condition-specific expert groups in 2018, in favour of a broader health prevention of non-communicable diseases group. It has been really encouraging to see the large number of countries sending representatives from their health ministries to these meetings, organised by Alzheimer Europe, and to experience the spirit of collaboration among this group.
Another European-level group brought together by Alzheimer Europe is the European Alzheimer’s Alliance (EAA) - a non-exclusive, multinational and cross-party group that brings together Members of the European Parliament (MEPs) to support Alzheimer Europe and its members in making dementia a public health priority in Europe. The EAA counted 95 members from 26 countries at the end of the year and continues to be one of the European Parliament’s largest interest groups. Two Alzheimer Europe lunch debates were organised in February (in Brussels) and December (online), hosted by EAA Vice-Chairpersons Christophe Hansen, MEP (Luxembourg) and Sirpa Pietikäinen, MEP (Finland), respectively. At the December event, we launched our report “Dementia as a European Priority – A Policy Overview” which takes stock of dementia policy at an EU level and sets out recommendations for future priorities across Europe.

The 2020 focus for our European Dementia Ethics Network was legal capacity and decision making and this was also a topic that was explored at one of the online sessions of our popular Alzheimer’s Association Academy, in December. The findings of the European Dementia Ethics Network were published in our 2020 report “Legal capacity and decision making: The ethical implications of lack of legal capacity on the lives of people with dementia”. Other reports were also developed with the support of the Robert Bosch Stiftung on the topic of intercultural care for policy makers and health and social care.

Iva Holmerová
Chairperson of Alzheimer Europe
As the Chairperson of the European Working Group of People with Dementia (EWGPWD), I am very honoured to be able to write this preface for the Alzheimer Europe Annual Report 2020.

What a trying time this has been, with the continuation of COVID-19 still affecting the world, its people and its economies. I send my upmost sympathy and healing thoughts for all those who have lost a loved one.

In 2020, the EWGPWD was only able to meet face-to-face on one occasion, so we had to adapt to meeting in other ways that some members had little or no experience of, coming together virtually and communicating in different ways in order to continue to contribute and work as a group.

For many of us, these meetings and the work that we do have become a lifeline. We started using the Zoom platform, working in smaller groups and keeping the times of meetings to a minimum as we all found it very difficult to concentrate, but we managed to keep going, to adapt to new ways of working and to carry on with our important public involvement (PI) activities.

The theme of the group’s work in 2020 was accessible events and meetings for people with dementia and we developed a set of recommendations on dementia-inclusive meetings, venues and travel. We also reflected on the topic of online meetings and events as this was an important issue during the pandemic. Despite the challenge of working in such a different manner, the group was nonetheless able to prepare its symposium for the virtual 31st Alzheimer Europe Conference in October. Members of the group decided to have a series of pre-recorded testimonials on the topic of the impact of COVID on people living with dementia. Several group members participated in the symposium and a number of meetings were organised by Alzheimer Europe, to support them in preparing and recording the speeches. The group also held a virtual booth at the conference, as well as organising a networking event with other delegates with dementia, and responding in writing to questions sent in by other conference delegates.

The EWGPWD was also invited to participate in consultations for various European projects during 2020, including RADAR-AD - a project in which members of the group have been heavily involved, and the VirtualBrainCloud project. We also participated in a qualitative research study on Advance Care Planning for the DISTINCT project, and during the summer some members of the group were able to take part in a consultation with a pharmaceutical company about various issues around conducting clinical trials during the pandemic.

Overall, the year was highly challenging for us both individually and as a group, but also very rewarding and positive, as we were able to meet this challenge head-on and continue with our contributions to advocacy and European-level research, all of which brings us great satisfaction and pride.

In October 2020, the group’s current two-year term began (2020-2022), and at that time, we welcomed some new members and sadly said goodbye to others. It’s great to see our membership growing with more countries getting involved and more national working groups forming, too.

I would like to thank all our members, both from the 2018-2020 group and the current group, for their determination to continue to adapt despite the difficult circumstances we have all found ourselves in. But our biggest appreciation, as always, is for the Alzheimer Europe staff for their considerable support and facilitation.

Chris Roberts
Chairperson of the European Working Group of People with Dementia
Executive Summary

In 2020, Alzheimer Europe:

- **Provided a voice to people with dementia and**
  - Involved 14 people with dementia from 11 European countries in its European Working Group of People with Dementia (EWGPWD)
  - Organised over 20 virtual meetings of the EWGPWD and consulted the group on its activities and EU funded projects
  - Developed recommendations on dementia-inclusive meetings, venues and travel
  - Dedicated a symposium at its Annual Conference to the impact of the COVID-19 pandemic on people with dementia

- **Made dementia a European priority and**
  - Highlighted the impact of the COVID-19 pandemic on dementia care and research dedicating a special section on its website and its newsletter to 246 COVID-19 related resources and information of relevance to people with dementia
  - Adopted policy positions on the issue of triage, the promotion of the wellbeing of people with dementia and the support of dementia research during the pandemic
  - Welcomed the adoption of national dementia strategies in Iceland, Germany and Spain and the decision of the Czech Republic, Netherlands and Norway to launch new strategies in 2021

- **Organised three meetings of the European Group of Governmental Experts on Dementia and involved representatives from 25 health ministries and observers from the European Commission, the Organisation for Economic Cooperation and Development (OECD) and the World Health Organization (WHO)**
  - Included 92 Members of the European Parliament from 26 European Union countries in the European Alzheimer’s Alliance
  - Continued its collaboration as an accredited organisation of the European Medicines Agency

- **Promoted a rights-based approach to dementia and**
  - Identified legal capacity and decision making as the priority of its 2020 focus
  - Brought together a group of legal and ethical experts with people with dementia, carried out a literature review, identified recommendations and published its report on “Legal capacity and decision making: The ethical implications of lack of legal capacity on the lives of people with dementia”
  - Developed and published reports on intercultural care for policy makers and health and social care workers thanks to the support of the Robert Bosch Stiftung
• Supported dementia research and
  • Carried out a mapping exercise of 489 EU-funded dementia research project representing a funding total of EUR 1.2 billion
  • Continued covering research developments via its website and social media
  • Published 11 monthly e-mail newsletters with a total of 662 news articles covering research news, as well as policy developments and activities of Alzheimer Europe, its projects and its members
  • Saw an increase of visitors to its website to 712,383 compared to 614,633 in 2019
  • Built on its social media presence and had 8,502 Facebook likes and 11,723 Twitter followers by the end of 2020
  • Organised its first Virtual Annual Conference “Dementia in a changing world” from 20–22 October 2020 with 719 participants from 43 countries which featured 260 speakers and 72 poster presentations

• Strengthened the European dementia movement and
  • Carried out an evaluation of its activities by its member organisation
  • Organised a series of capacity building workshops for its members as part of its Alzheimer’s Association Academy
  • Hosted five meetings of the Alzheimer Europe Board as well as a Virtual Annual General Meeting
  • Continued as a full member of the European Patients’ Forum and the European Disability Forum
  • Collaborated with INTERDEM, the European Alzheimer’s Disease Consortium (EADC) and the European Academy of Neurology (EAN)
  • Contributed to the EAN guidelines on management issues in dementia and the EAN/EADC position on the diagnosis and disclosure of mild cognitive impairment
  • Collaborated with INTERDEM, the European Alzheimer’s Disease Consortium (EADC) and the European Academy of Neurology (EAN)
  • Contributed to the EAN guidelines on management issues in dementia and the EAN/EADC position on the diagnosis and disclosure of mild cognitive impairment

• Carried out the following project-related activities
  • continued its involvement in a number of EU funded projects by representing the views of people with dementia and their carers in the research consortium, by contributing to the ethical discussions and by supporting the communication and dissemination activities towards a non-scientific audience:
    • AD-Detect-Prevent (Presymptomatic AD detection and prevention)
    • AMYPAD (Amyloid imaging to prevent Alzheimer’s disease)
    • EPAD (European Prevention of Alzheimer’s Dementia)
    • Neuronet (Efficiently networking European neurodegeneration research)
EXECUTIVE SUMMARY

- PARADIGM (Patients active in research and development for an improved generation of medicines)
- PRODEMOS (Prevention of Dementia using Mobile phone Applications)
- RADAR-AD (Remote assessment of disease and relapse – Alzheimer’s disease)
- RECOGNISED (Retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways and identification of patients at risk of dementia)
- VirtualBrainCloud (Personalised Recommendations for Neurodegenerative Disease)

- started its collaboration with
- EUProjects (Multi-modal precision prevention toolbox for dementia in Alzheimer’s disease)

- supported the following EU projects
  - DISTINCT (Dementia: Intersectorial strategy for training and innovation network for current technology)
  - MinD (Designing for People with Dementia)
  - MIRIAD (Multi-omics interdisciplinary research integration to address dementia diagnosis)
  - SPAN+ (Empowering people with dementia)

- developed a number of projects funded thanks to the support of its corporate sponsors and other partners
- organised a European Parliament lunch debate on “The Innovative Medicines Initiative (IMI): Advancing Alzheimer’s research through private-public partnerships”, hosted by Christophe Hansen, MEP (Luxembourg), in February and an online workshop on “Maintaining dementia as a public health and research priority during the COVID-19 pandemic”, hosted by Sirpa Pietikäinen, MEP (Finland) in December
- convened three company round table meetings bringing together representatives of industry and national Alzheimer’s associations
- published three editions of the Dementia in Europe magazine
- developed a policy brief “Dementia, a European priority” highlighting the past EU activities in support of dementia and identifying recommendations for future action at European and national level
- expanded its Clinical Trials Watch and made available on its website dementia-friendly information on 8 phase II and 6 phase III clinical trials conducted in Europe
- continued the mapping exercise of data sharing practices in European research projects thanks to the support of Gates Ventures
AE core activities

In 2020, Alzheimer Europe received an operating grant in the framework of the European Union’s Health Programme which provided the funding for the organisation’s following core activities.

Objective 1: Providing a voice to people with dementia and their carers

The representation of people with dementia in policy discussions, service development and research is still underdeveloped in many countries. Thanks to its European Working Group of People with Dementia (EWGPWD) from 12 different countries, Alzheimer Europe was in a position to provide input to several European projects and initiatives, as well as to Alzheimer Europe’s own projects and activities, thereby ensuring that the voices of people with dementia influence research, care and policy.

A key priority of the 2020 Work Plan was for the EWGPWD to explore the accessibility of meetings and travel for people with dementia. The group decided, in addition, to explore the use of and accessibility of virtual meetings. This coincided with the need for them to switch to virtual meetings as all travel and attendance at meetings were cancelled in Europe during the COVID-19 pandemic. The EWGPWD had 1 face-to-face meeting in February 2020 in Brussels but in March 2020, due to the 2020 COVID-19 pandemic, all planned face-to-face meetings of the EWGPWD had to be cancelled. The group has participated in over 20 virtual meetings and despite the difficulties and challenges outlined in their report, all members of the group will continue working online until it is safe and possible to resume face-to-face meetings.

The Chair of the EWGPWD (2018–2020), Helen Rochford-Brennan, actively participated in the meetings of the Board of Alzheimer Europe in 2020. After the formation of the new group for the 2020 to 2022 term of office, she continued as a normal member of the working group and was replaced as Chair by Chris Roberts (previously Vice Chair). Two further Vice Chairs were appointed by the EWGPWD, namely Bernd Heise from Germany and Kevin Quaid from Ireland.

Between January 2020 and October 2020, the group had the following members:

- Chair: Helen Rochford-Brennan, Ireland.
- Vice-Chair: Chris Roberts, UK – England, Wales and Northern Ireland.
- Members: Idalina Aguiar, Portugal; Stefan Eriksson, Sweden; Tomaž Grišinič, Slovenia; Amela Hajrič, Bosnia & Herzegovina; Carol Har-greaves, UK – Scotland; Bernd Heise, Germany; Nina Baláčková, Czech Republic; Petri Lampinen, Finland; Thomas Maurer, Switzerland; Angela Pototschnigg, Austria; Geert Van Laer, Belgium.

Since October 2020, the group has had the following members:

- Vice-Chairs: Bernd Heise, Germany and Kevin Quaid, Ireland.
- Members: Helen Rochford-Brennan, Ireland; Idalina Aguiar, Portugal; Stefan Eriksson, Sweden; Tomaž Grišinič, Slovenia; Nigel Hullah, UK – England, Wales and N. Ireland; Margaret McCallion, UK – Scotland; Danny McDonald, UK – Scotland; Petri Lampinen, Finland; Angela Pototschnigg, Austria; Geert Van Laer, Belgium; Erla Jónsdóttir (Iceland).

Two additional women had expressed interest in joining the EWGPWD (one from Denmark, one from the Netherlands) and attended one virtual meeting of the group. However, they both decided not to join for different reasons.

Chris Roberts, the 2020-2022 Chairperson of the European Working Group of People with Dementia, speaking at Alzheimer Europe’s European Parliament lunch debate, 18 February 2020

Carer Nelida Aguiar asks a question at Alzheimer Europe’s European Parliament lunch debate, Brussels, 18 February 2020
In 2020, the EWGPWD and/or its members also contributed towards:

- Alzheimer Europe activities (30th Alzheimer Europe conference, Alzheimer’s Association Academy, ethics report on legal capacity and decision making, Alzheimer Europe newsletter)

- EU projects in which Alzheimer Europe is involved (PARADIGM, VIRTUAL BRAIN CLOUD, RADAR-AD, SPAN+, Miriade and DISTINCT)

Objective 2: Making dementia a European priority

Initially, Alzheimer Europe had planned on carrying out a mapping exercise and comparison of national training and education programmes for healthcare professionals involved in the diagnosis, treatment, management and care of people with dementia. Unfortunately, due to the COVID-19 pandemic, it became impossible for the national member organisations to respond to the survey. In addition, organisations highlighted the need to exchange information and identify good practices on national responses to the pandemic.

As a result, Alzheimer Europe responded to the pandemic and included regular news on the COVID-19 pandemic in its monthly newsletters and developed an online resource centre which provided references in the following 11 categories:

1. Information for people with dementia
2. Advice for caregivers and family members
3. Information for minority ethnic groups
4. COVID-19 and intellectual disabilities
5. Mental health resources
6. COVID-19 in numbers: epidemiology
7. Global resources
8. EU resources
9. National country resources
10. General, scientific and ethical resources
11. Mental health resources

A total of 80 COVID-19 related news items were included in Alzheimer Europe’s newsletter and 246 resources were included on the Alzheimer Europe website.

In addition, Alzheimer Europe convened a number of meetings with its national member organisations (2 April and 10 June) and with the European Group of Governmental Experts on Dementia (24 March, 4 June and 8 December) where national representatives updated others on their respective strategies and initiatives to protect and support people with dementia and their caregivers during the pandemic.

Finally, Alzheimer Europe adopted the following policy positions or recommendations:

- 3 April – Alzheimer Europe position regarding the allocation of scarce medical resources for intensive care services during the COVID-19 pandemic
- 14 April – Alzheimer Europe recommendations on promoting the wellbeing of people with dementia and carers during the COVID-19 pandemic
- 28 July – Alzheimer Europe position on supporting dementia research in unprecedented circumstances.
Alzheimer Europe organised three online meetings of the of the European Group of Governmental Experts on Dementia. These meetings were attended by national health ministry officials from 25 European countries (Austria, Belgium – Flanders, Bulgaria, Croatia, Czech Republic, Estonia, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Latvia, Malta, Netherlands, Norway, Portugal, Poland, Slovenia, Sweden, Switzerland, UK – England and the UK– Scotland). In addition, non-country stakeholders were also represented in the meetings: Alzheimer Europe, European Commission (DGs SANTE and RTD), Organisation for Economic Cooperation and Development, and the World Health Organization (WHO). These meetings were primarily focused on the COVID-19 pandemic, how it affected people with dementia and their carers, and how governments were responding.

2020 also saw a number of key developments at national, European and global level, to which Alzheimer Europe was able to contribute. On a national level, Alzheimer Europe welcomed the launch of the national dementia strategies in Iceland, Germany and Spain, as well as the announcement from the Czech Republic, Netherlands and Norway, of their intention to launch new dementia strategies in 2021.

At a European level, in 2020, Alzheimer Europe wrote to both Health Commissioner, Stella Kyriakides, and Vice-President of Democracy and Demography, Dubravka Suica, emphasising the importance of dementia as a policy priority. Owing to a number of MEPs leaving the Parliament, the European Alzheimer’s Alliance (EAA) saw a slight reduction in its membership, with 93 MEPs as at the end of 2020. Alzheimer Europe will therefore make increasing the members a focus of its work in 2021.

Alzheimer Europe also worked closely with its member associations and organised three meetings with public affairs representatives (February, April and June) to discuss EU policy developments, national lobbying and campaigning activities, as well as ongoing work of national associations to respond to the COVID-19 pandemic. As a result of the pandemic, only the February meetings were held in-person, with the others were organised virtually.
Alzheimer Europe continued its collaboration with the European Medicines Agency (EMA) in 2020 as an accredited patient organisation and as a full member of EMA’s Patients’ and Consumers’ Working Party (PCWP). A member of the European Working Group of People with Dementia also contributed to an EMA scientific advice procedure.

Alzheimer Europe also continued to engage with the World Health Organization (WHO), sharing its work with our members and contributing to its ongoing work in relation to the Global Action Plan on Dementia.

Objective 3: Promoting a rights-based approach to dementia

As in previous operating grants, Alzheimer Europe continued to focus on ethical issues in 2020 and this led to the publication of a report entitled “Legal capacity and decision making: The ethical implications of lack of legal capacity on the lives of people with dementia”. This report addresses ethical issues surrounding legal capacity insofar as these relate to the lives and wellbeing of people with dementia.

Having legal capacity means being considered as a subject before the law. It also means having certain rights (including human rights) and having the opportunity to exercise those rights, albeit with appropriate support if needed, that is acceptable and freely chosen. The aims of this report were:

- to raise awareness about situations and practices surrounding legal capacity.
- to highlight grey zones and controversial issues linked to these and in relation to human rights and ethics, and
- to make recommendations to ensure that the rights and wellbeing of people with dementia are respected and promoted.

The report provides a balanced and in-depth discussion of relevant issues and contains recommendations for relevant stakeholders and actors.

The report was drafted by the ethics working group, which was set up by Alzheimer Europe in 2020 to explore legal capacity and dementia, drawing on the expertise and experience of the different members of the group. The experts had backgrounds in dementia, law, ethics, restrictions of freedom, human rights, guardianship measures, psychology, policy, care and research. The working group included the Chair of the European Working Group of People with Dementia and a current supporter and former carer of a person with dementia. Because of the COVID-19 pandemic, the group had to operate virtually but still managed to address a broad range of issues and perspectives, and arrive at a consensus on the different positions reflected in the document.

The ethics group was chaired by Dianne Gove from Alzheimer Europe and the members of the group were Carmel Geoghegan (Ireland), Jean Georges (Luxembourg), Alistair Niemeijer (Netherlands), Jim Pearson (United Kingdom), Catherine Quinn (United Kingdom), Sebastian Ritzi (Germany), Helen Rochford Brennan (Ireland), Matthé Scholten (Germany) and Maria Do Rosário Zincke Dos Reis (Portugal).

The report was mainly targeted at health and social care professionals, lawyers and legal representatives (i.e. all those who may at some point may play a role in decisions related to the exercise and/or loss of legal capacity of people with dementia). In addition, a shorter report, for a broader audience, was prepared by the expert working group and can be located via a link in the full report or directly on Alzheimer Europe’s website.

In addition, thanks to the support of the Robert Bosch Stiftung, Alzheimer Europe was able to develop a short guide entitled “Intercultural dementia care: a guide to raise awareness amongst health and social care workers”, which was published in English, German, French, Bulgarian and Italian, and a Policy Statement. Work also continued on the online database of intercultural dementia care initiatives, which will eventually be transformed into a more user-friendly, sophisticated system.
Objective 4: Supporting dementia research

An important priority of Alzheimer Europe’s actions in the field of supporting dementia research was a mapping exercise of EU-funded research projects. As part of this exercise, a total number of 489 projects were identified which were supported with a total amount of close to EUR 1.2 billion. The next table provides a breakdown of projects according to funding mechanism and total amount of funding:

<table>
<thead>
<tr>
<th>Project</th>
<th>Ongoing projects</th>
<th>Closed projects</th>
<th>Total cost (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORDIS – H2020</td>
<td>223</td>
<td>114</td>
<td>469 034 793,98</td>
</tr>
<tr>
<td>CORDIS – FP7</td>
<td>145</td>
<td>0</td>
<td>464 678 142,78</td>
</tr>
<tr>
<td>JPND database (2011–2016)</td>
<td>74</td>
<td>2</td>
<td>158 079 019,86</td>
</tr>
<tr>
<td>JPND website (2017–2019)</td>
<td>23</td>
<td>18</td>
<td>31 822 000</td>
</tr>
<tr>
<td>IMI</td>
<td>17</td>
<td>8</td>
<td>350 806 563</td>
</tr>
<tr>
<td>AAL</td>
<td>35</td>
<td>5</td>
<td>64 651 975</td>
</tr>
<tr>
<td>EU Health Programme</td>
<td>21</td>
<td>1</td>
<td>6 771 116,30</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>489</strong></td>
<td><strong>140</strong></td>
<td><strong>1 177 924 019,30</strong></td>
</tr>
</tbody>
</table>

For the dissemination of research findings via its newsletter, website and conference, Alzheimer Europe ensured that it did not only focus on basic and clinical science, but also involved researchers and academics with a psychosocial, care, mental health, socio-economic or health systems background. Particular attention was also paid to covering research news and identifying interesting developments from countries whose gross national income is less than 90% of the Union average.

In 2020, Alzheimer Europe published 11 monthly editions of its e-newsletter, with the months of July and August being combined into one. These e-newsletters contained information on Alzheimer Europe’s activities, those of its member organisations and those of the European Alzheimer’s Alliance of MEPs and the European Group of Governmental Experts on Dementia (both formed by Alzheimer Europe).

Updates on European projects in which Alzheimer Europe is involved were also shared, as were relevant policy initiatives and developments at the national and European levels, scientific advances, human interest stories, new resources and publications, and job opportunities in the dementia field. Finally, Alzheimer Europe also made sure to include a number of accounts written by people living with dementia, with many members of the EWGPWD contributing to this section, as well as members of national dementia working groups in our member countries.

As a result of the global COVID-19 pandemic, Alzheimer Europe decided, from March onwards, to develop a repository of valuable online resources. Alzheimer Europe also closely monitored the situation and included relevant news developments for people with dementia and their carers in a special COVID-19 section of the newsletter and website.

A total of 628 articles were featured in Alzheimer Europe’s 2020 monthly e-newsletters (589 in 2019). They can be broken down into categories, as follows:

<table>
<thead>
<tr>
<th>Subject</th>
<th>Number of articles (2020)</th>
<th>Number of articles (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 situation</td>
<td>80</td>
<td>n/a</td>
</tr>
<tr>
<td>Activities and projects of Alzheimer Europe</td>
<td>184</td>
<td>127</td>
</tr>
<tr>
<td>European policy developments in the field of dementia and European Alzheimer’s Alliance</td>
<td>70</td>
<td>73</td>
</tr>
<tr>
<td>National policy developments</td>
<td>31</td>
<td>47</td>
</tr>
<tr>
<td>Activities and projects of AE member organisations</td>
<td>70</td>
<td>135</td>
</tr>
<tr>
<td>Scientific developments</td>
<td>139</td>
<td>132</td>
</tr>
<tr>
<td>Dementia in Society and “Living with dementia” section</td>
<td>29</td>
<td>40</td>
</tr>
<tr>
<td>New resources and publications, education and job opportunities</td>
<td>49</td>
<td>35</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>652</strong></td>
<td><strong>589</strong></td>
</tr>
</tbody>
</table>
There is a noticeable reduction in the number of articles on national policy developments and on members’ activities, but this is due to many articles covering policy developments and members’ activities being related to the COVID-19 pandemic, and therefore published in the dedicated COVID news section.

In 2020, Alzheimer Europe’s website saw a significant increase in visitors compared to 2019.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>60,650</td>
<td>54,058</td>
</tr>
<tr>
<td>February</td>
<td>67,339</td>
<td>57,031</td>
</tr>
<tr>
<td>March</td>
<td>62,647</td>
<td>60,311</td>
</tr>
<tr>
<td>April</td>
<td>64,467</td>
<td>50,521</td>
</tr>
<tr>
<td>May</td>
<td>63,726</td>
<td>44,778</td>
</tr>
<tr>
<td>June</td>
<td>50,315</td>
<td>40,898</td>
</tr>
<tr>
<td>July</td>
<td>41,138</td>
<td>37,000</td>
</tr>
<tr>
<td>August</td>
<td>44,691</td>
<td>42,622</td>
</tr>
<tr>
<td>September</td>
<td>64,686</td>
<td>60,146</td>
</tr>
<tr>
<td>October</td>
<td>67,309</td>
<td>67,423</td>
</tr>
<tr>
<td>November</td>
<td>58,122</td>
<td>67,416</td>
</tr>
<tr>
<td>December</td>
<td>67,303</td>
<td>52,597</td>
</tr>
<tr>
<td>Total:</td>
<td>712,393</td>
<td>614,633</td>
</tr>
</tbody>
</table>

The organisation also continued to develop its social media presence, on Facebook and Twitter, but also on LinkedIn and YouTube. Alzheimer Europe’s Facebook page registered 8,502 “likes” at the end of 2020, an increase from 8,191 likes at the end of 2019. As for Twitter, the association had reached 11,723 followers at the end of 2020 (10,600 at the end of 2019).

All Alzheimer Europe team members who are involved in projects and attend Alzheimer Europe events are active Twitter users, tweeting from events where they represent the organisation. The total number of Tweets by Alzheimer Europe and its team members in 2020 was 2,313 (2,700 in 2019) and tweet impressions reached 3.1 million (3.49 million in 2019).

Twitter is also used by Alzheimer Europe as a means to increase website traffic. The table below shows Alzheimer Europe’s own Twitter account activity in 2020:

<table>
<thead>
<tr>
<th>Month</th>
<th>Tweets</th>
<th>Tweet impressions</th>
<th>New followers</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>83</td>
<td>162,000</td>
<td>120</td>
</tr>
<tr>
<td>February</td>
<td>62</td>
<td>140,000</td>
<td>158</td>
</tr>
<tr>
<td>March</td>
<td>65</td>
<td>137,000</td>
<td>60</td>
</tr>
<tr>
<td>April</td>
<td>68</td>
<td>121,000</td>
<td>79</td>
</tr>
<tr>
<td>May</td>
<td>61</td>
<td>129,000</td>
<td>72</td>
</tr>
<tr>
<td>June</td>
<td>104</td>
<td>144,000</td>
<td>111</td>
</tr>
<tr>
<td>July</td>
<td>52</td>
<td>90,700</td>
<td>76</td>
</tr>
<tr>
<td>August</td>
<td>49</td>
<td>96,200</td>
<td>49</td>
</tr>
<tr>
<td>September</td>
<td>90</td>
<td>132,000</td>
<td>117</td>
</tr>
<tr>
<td>October</td>
<td>186</td>
<td>236,000</td>
<td>162</td>
</tr>
<tr>
<td>November</td>
<td>88</td>
<td>167,000</td>
<td>96</td>
</tr>
<tr>
<td>December</td>
<td>101</td>
<td>163,000</td>
<td>46</td>
</tr>
<tr>
<td>Total:</td>
<td>1,009</td>
<td>1,717,900</td>
<td>1,146</td>
</tr>
</tbody>
</table>

Unlike more medical conferences organised in this field, the Alzheimer Europe Conference attracted a mix of health and social care professionals, researchers and academics, but also people with dementia, family carers and policy makers with an interest in dementia. Alzheimer Europe

On World Alzheimer’s Day, Alzheimer Europe campaigned about the urgent need to support dementia research

**Urgent call to support dementia research**

“We urge all governments, funding bodies and research institutions to work together to ensure that the negative impacts of the pandemic are mitigated and that dementia is re-prioritised with the necessary resources and funding to improve our understanding of the underlying causes of dementia and our ability to provide the highest quality care and support.”

Jean Georges, Executive Director, Alzheimer Europe

#WorldAlzheimersDay
involved its European Working Group of People with Dementia and the INTERDEM network of psychosocial researchers in the organisation and planning of the conference.

The 30th Alzheimer Europe Conference (#30AEC) took place online, from 20–22 October 2020. The event was organised under the theme of “Dementia in a changing world” and was attended by 719 participants from 43 countries (in 2019 The Hague conference was attended by 981 participants from 46 countries), including 39 people with dementia. The programme featured 260 speakers and 72 poster presentations, sharing their research, projects and experiences in an atmosphere of collaboration. The five plenary sessions were dedicated to “Dementia in a changing world”, “Diagnosis and medical management”, “Building dementia-inclusive societies”, “Maintaining dementia as a European priority” and “From research and innovation to clinical and care practice”.

In addition to the 5 plenaries, delegates at #30AEC had a choice of 24 different parallel sessions, and 6 special symposia organised by the European Working Group of People with Dementia and the sponsors of the Alzheimer Europe Conference. The conference ended with an invitation to attend the 31st Alzheimer Europe Conference (#31AEC) in Bucharest, Romania in 2021.

In the evaluation of the Annual Conference, 99.04% of participants said that they would be happy to recommend the Alzheimer Europe Conference to a colleague.

Objective 5: Strengthening the European dementia movement

As the operating grant activities under the current framework programme are coming to an end, Alzheimer Europe surveyed its members to identify how useful the various activities and initiatives of the organisation were for its members. The responses provided by the Alzheimer Europe members will be discussed at a meeting of the organisation in February 2021 and will form the basis for the development of the new Strategic Plan of Alzheimer Europe for the years 2021–2026 which will be developed as part of the organisation’s 2021 operating grant.
As in previous years, this priority primarily targeted the volunteers and staff members of national Alzheimer’s associations. Alzheimer Europe therefore organised a number of capacity building workshops and meetings for organisations to exchange on activities, projects and initiatives at national level. Special attention was paid to prioritise the need of associations from countries whose gross national income is less than 90% of the Union average.

In 2020, Alzheimer Europe organised meetings and capacity building workshops on 19 February, 2 April, 10 June, 24 November, 1 December and 7 December. Only the first of these meetings was a face-to-face meeting with all other meetings being organised virtually:

The following issues were included as topics for these capacity building workshops:

- National campaigning activities
- National training and education programmes for healthcare professionals involved in the diagnosis, treatment, management and care of people with dementia
- National responses to the COVID-19 pandemic
- Lockdown exit strategies and implications for people with dementia and carers
- Involving people with dementia in the development of and in research linked to medicinal products
- Health data governance and data sharing: dementia research, patient privacy and EU policy
- Legal capacity and decision making
- Developing and running national working groups of people with dementia.

The Alzheimer Europe Board met five times (February, May, June, September and December) during the year and monitored the activities and finances of the organisation in relation to the agreed upon Work Plan and Budget. With the exception of the first meeting, these took place in an online format.

The Annual General Meeting of Alzheimer Europe took place virtually on 5 October. At the meeting, the delegates adopted Alzheimer Europe’s 2019 Annual and Financial reports and approved the 2021 Work Plan and Budget. The members also elected a new Board of the association for the period 2020–2022.

As in previous years, Alzheimer Europe was an active member of the European Patients’ Forum (EPF) and European Disability Forum (EDF) and contributed, alongside other European organisations, to the development of cross-disease positions on EU consultations and legislative proposals. In 2020, Alzheimer Europe was particularly involved in the work of the EU4Health Civil Society Alliance, which worked to ensure health remained a priority at an EU level, as well as pushing for an increased budget allocation in the Multiannual Financial Framework (MFF). Alzheimer Europe also continued to support the EDF in their work advocating for a European Disability Strategy.

Alzheimer Europe also continued its cooperation with INTERDEM, a pan-European research network for psychosocial interventions in dementia. The network organised its annual meeting prior to the Virtual Alzheimer Europe Conference and organised a number of parallel sessions during the event. Dianne Gove and Ana Díaz represented Alzheimer Europe at this INTERDEM meeting.

The Executive Director of Alzheimer Europe represented the organisation at the meetings of the European Alzheimer’s Disease Consortium, a network of memory clinics and centres involved in clinical research.

In 2020 Alzheimer Europe also continued its collaboration with the European Academy of Neurology (EAN) and the organisation’s Executive Director joined the Management Board of the EAN Dementia Panel as a member and contributed to the Task Force for the development of a guideline on medical management issues in dementia. He also contributed to the position statement on diagnostic disclosure for patients with mild cognitive impairment developed jointly by an EADC/EAN working group.
Other activities and projects

Involvement in EU projects

Alzheimer Europe was a full partner in a number of projects funded by the European research programmes Horizon2020, FP7 and the Innovative Medicines Initiative. In these projects, the organisation typically ensured that the views of people with dementia, carers and Alzheimer’s associations were included, contributed to the discussion of the ethical issues raised by the projects and supported or lead the dissemination activities. In 2020, Alzheimer Europe was a full partner in the following projects:

AD-Detect-Prevent

The two-year AD-Detect-Prevent project, which officially started on 1 November, aims to develop an easily accessible, user-friendly and motivating digital medical device called AD Detect & Prevent. If successful, this will offer personalised prevention programmes in the form of computerised cognitive training and behavioural/lifestyle interventions in one seamless product. Whilst predominantly targeted at people at risk of developing Alzheimer’s dementia, it may eventually be valuable for people with Mild Cognitive Impairment or mild dementia.

Alzheimer Europe was represented in this project by Dianne Gove and Ana Diaz. In 2020, they:

- presented the past and planned contribution of the EWGPWD in the project at the 3rd Steering Committee Meeting and Partner Workday, which was eventually held virtually
- helped organise a webinar and supported the Chair of the European Working Group of People with Dementia to prepare a presentation, which was eventually delivered by Carmel Geoghegan, who regularly supports her activities in the EWGPWD.

AMYPAD

The “Amyloid imaging to prevent Alzheimer’s disease” project aims to improve the diagnostic workup of patients suspected to have Alzheimer’s disease and their management. The consortium is led by Stichting VUmc and GE Healthcare Life Sciences. The partners aim to improve knowledge of the natural history of Alzheimer’s disease in a pre-symptomatic stage, in order to better select patients for trials. In addition, they monitor changes in beta amyloid deposition in the brain in order to quantify the impact of novel therapies.

Alzheimer Europe was represented by Jean Georges, Cindy Birck and Dianne Gove in this project. In 2020, they:

- represented Alzheimer Europe in the AMYPAD Executive Committee and its weekly telephone conference and presented regular updates on the projects’ communication and dissemination activities,
- co-led the work package on ethics, communication and dissemination,
- organised and chaired the monthly communication teleconference meetings,
- coordinated the production and the regular maintenance of the communication tools (i.e. website, newsletter, Twitter, Research Gate, slide deck, YouTube),
- provided social media support for AMYPAD presenters at selected international and European conferences,
- contributed to the internal track of dissemination activities,
- developed the AMYPAD contributor list and followed up the AMYPAD authorship policy and publication approval policy,

Alzheimer Europe was represented in this project by Dianne Gove and Ana Diaz. In 2020, they:

- provided feedback on presentations and communications materials for conferences and dissemination materials targeted at the general public.
OTHER ACTIVITIES
AND PROJECTS

• represented the AMYPAD comms team in the Neuronet communication expert community,
• attended the online General Assembly meeting,
• contributed to the efficient communication of the project via AE website, newsletter and events.

The AMYPAD project was also presented by Gill Farrar at the 30th Alzheimer Europe Conference as part of the Neuronet annual event and had a branded virtual booth during the conference. The project also had the opportunity to hold a Featured Research Session, consisted of four oral presentations, at the online 2020 Alzheimer’s Association International Conference (AAIC); Alzheimer Europe organised a live Q&A where delegates had the opportunity to interact with the AMYPAD chairs and speakers.

EPAD

The European Prevention of Alzheimer’s dementia (EPAD) initiative was a collaborative research effort to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. Led by the University of Edinburgh, the project established a European-wide register of research participants.

Alzheimer Europe was represented by Jean Georges, Cindy Birck and Dianne Gove in this project. In 2020, they:

• co-led the work package on dissemination and participated in the monthly work package teleconferences,
• coordinated the production and the regular maintenance of the communication and dissemination tools (i.e. website, newsletter, social media channels, Research Gate, YouTube),
• drafted and finalised the last EPAD comms deliverable D6.5 (Impact and evaluation report),
• coordinated the development of a new section dedicated to the EPAD sample and data on the project’s website,
• developed a final video showcasing the EPAD project with key pictures, photos from the various EPAD events and rolling credits that named everyone who was involved in the project,
• represented Alzheimer Europe in the Publications Approval Committee and Clinical Development Executive (CDEx),
• represented the EPAD comms team in the Neuronet communication expert community,
• attended the online General Assembly meeting and presented the projects’ communication and dissemination activities,
• participated and contributed to the EPAD Change Management Team tasked with preparing the sustainability of the programme after the IMI funding period,
• contributed to the efficient communication of the project via AE website, newsletter and events,
• contributed to telephone conferences of the ethics working group, reviewed the final ethics deliverable D8.5 (Final report on ethical, legal and social implications and recommendations) and co-authored an article on the Participant Panel.

The EPAD project was also presented by Rodrigo Barnes and Colin Veal at the 30th online Alzheimer Europe Conference, as part of the Neuronet annual event.

EU-FINGERS

The JPND-funded project, EU-FINGERS (Multi-modal precision prevention toolbox for dementia in Alzheimer’s disease), kicked off in 2020 with the aim of advancing preventive strategies for risk reduction and prevention of cognitive decline and Alzheimer’s dementia. An important outcome of this project will be the “Multimodal Precision Prevention Toolbox”. This Toolbox will include different tools enabling the next generation of clinical trials, to identify precision prevention strategies for Alzheimer’s dementia. Precision Medicine takes into account individual characteristics, in terms of biology, lifestyle and environment, to optimize disease treatment and prevention.

Alzheimer Europe was involved in the Patient and Public Involvement (PPI) activities and co-led the communication activities of the project. Alzheimer Europe was represented by Jean Georges, Ana Diaz, Cindy Birck and Dianne Gove. In 2020, they:
OTHER ACTIVITIES
AND PROJECTS

- participated in the online kick-off meeting in March and the online general assembly meeting in December,
- identified all third parties interested in the activities and results of the project,
- coordinated the production and regular maintenance of the project’s social media channels (i.e. Twitter, LinkedIn),
- provided support in the development of the project’s website,
- coordinated the production of an article highlighting the launch of the project which was published in the AE Dementia in Europe magazine in June,
- contributed to the efficient communication of the project via AE website, newsletter and events,
- started to plan the PPI activities including the development of the best strategy to involve people with AD across the disease continuum despite the COVID 19 pandemic,
- developed the relevant materials for the Advisory Board members (i.e. terms of reference with information about the project and the Advisory Board, expression of interest to take part in the informative meetings, form to formally join the Advisory Board),
- in collaboration with project partners identified several members from the countries involved in the project with an interest in joining the Advisory Board.

Neuronet

Neuronet is an IMI-funded coordination and support action (CSA), which received funding in 2019 and which aims to boost synergy and collaboration between IMI projects working on neurodegenerative diseases (NDD) such as Alzheimer’s disease and Parkinson’s disease. Neuronet aims to collect and analyses information and assets from the various NDD initiatives in the IMI portfolio, aiming to identify gaps, enhance visibility and multiply the impact of the portfolio as a whole. To achieve this, Neuronet developed a Knowledge Base platform and an asset map of the portfolio, among other resources. The Neuronet consortium is led by SYNAPSE Research Management Partners and Janssen.

Neuronet Scientific Coordination Board meeting, Madrid, January 2020

Alzheimer Europe was represented by Jean Georges, Christophe Bintener, Cindy Birck and Angela Bradshaw. In 2020, they:

- co-led the work package on dissemination and outreach,
- contributed to work packages on projects & impact analysis, programme integration), tools & services and CSA management and sustainability and co-authored a number of project deliverables,
- authored the following deliverables: Interim report on dissemination activities, Public event proceedings and videos – Year 1, First version of guidance on standards and practices for protecting data privacy
- coordinated the production and the regular maintenance of the communication tools and channels (i.e. website, newsletter, social media channels),
- contributed to the design development of the Knowledge Base and updated modules on publications, deliverables, tools and events,
- coordinated and chaired meetings of the Communications Expert Community,
- organised and coordinated the Neuronet sessions at the virtual Annual Conference of Alzheimer Europe where they held a presentation and moderated a session,
- Organised a European Parliament Lunch Debate on “The Innovative Medicines Initiative (IMI): Advancing Alzheimer’s research through private-public partnerships” at which the project was presented,
- attended the fortnightly teleconference meetings of the Executive Committee and monthly work package teleconference meetings,
- moderated the working group on patient privacy and ethics,
- participated in the working groups on data sharing, HTA/regulatory affairs and sustainability,
- contributed to the development of a research paper,
- contributed to the efficient communication of the project via AE website, newsletter and events,
- attended the consortium meetings and updated the consortium on the communication and dissemination activities.

EU-FINGERS online consortium meeting, 14 December 2020

Efficiently Networking European Neurodegeneration Research
PARADIGM

PARADIGM is a European IMI-funded project, which started in March 2018 and came to an end in November 2020. PARADIGM sought to improve the involvement of patients in the process of developing medicines. Alzheimer Europe was part of this project and its role was to ensure that the voices of people affected by dementia were taken into account in the project.

- Contributed to the development, testing and dissemination of the Monitoring and Evaluation Framework developed by the project.
- Contributed to the development of all PARADIGM tools.
- Co-led the development of two of the PARADIGM tools including their development, integration of feedback from internal and public consultations, collaboration with design team and dissemination activities.
- Facilitated the involvement of members of the EWGPWD and their supporters in several online project meetings and webinars and in the PARADIGM-PREFER workshop.
- Organised consultations with members of the EWGPWD and of Alzheimer associations in relation to the Monitoring and Evaluation Framework and PARADIGM tools.
- Participated and co-led sessions in several project workshops, including a workshop dedicated to Public Involvement in medicines development in the CEE region.
- Participated in all sessions of the 2020 virtual Patient Engagement Open Forum, providing presentations of the tools co-led by AE.
- Participated in all PARADIGM Question and Answer sessions for patient communities.
- Co-authored papers published in peer-reviewed journals.
- Contributed to the dissemination of the project and its findings via AE’s electronic newsletter, Dementia in Europe Magazine and social media.

The PRODEMOS (Prevention of Dementia using Mobile phone Applications) project kicked off in January 2018. This project aims to make an evidence-based dementia prevention strategy using mobile Health accessible to those at increased risk of dementia who are usually not reached by preventive medicine. The project will target socio-economically deprived populations in the EU and a population at risk of dementia in China. The final aim is to implement the mHealth platform in a culturally appropriate form in a range of health care settings.

Alzheimer Europe supported the communication and dissemination activities and was represented by Jean Georges and Cindy Birck. In 2020, they:

- attended the online general assembly meeting,
- participated in the monthly telephone conferences of the PRODEMOS WP leads,
- started the planning and development of the news items for the PRODEMOS mHealth platform,
- contributed to the efficient communication of the project via AE website, newsletter and events.
RADAR-AD

The RADAR-AD (Remote Assessment of Disease and Release – Alzheimer’s disease) project funded by the Innovative Medicines Initiative started in 2019. The ultimate goal of the project is the development and validation of technology-enabled, quantitative and sensitive measures of functional decline in people with early-stage Alzheimer’s disease.

Alzheimer Europe’s role in the project was to lead and support the patient and public involvement activities of the project. The organisation was represented by Ana Diaz and Dianne Gove in this project. In 2020, they:

- attended the General Assembly which was held virtually,
- took part in regular online meetings with researchers from various work packages to ensure the mutually beneficial and ongoing meaningful involvement of the European Working Group of People with Dementia, their supporters and two people with MCI in the RADAR-AD Patient Advisory Board,
- organised a series of online consultations with the full RADAR-AD Patient Advisory Group, as well as several activities (by email, zoom and telephone) with the Core Group of the RADAR-AD Patient Advisory Group on a range of topics, gave feedback on the participant manual and reviewed changes to the protocol of the trial, as well as to information sheets and consent forms for the sub-study,
- supported other members of the WP team conducting qualitative research on ethical issues with members of the RADAR-AD Patient Advisory Board,
- co-authored an article on functional domains.

RECOGNISED

The RECOGNISED project (Retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways and identification of patients at risk of dementia) started in January 2020 and is funded by Horizon 2020 for a 4-year period. RECOGNISED will apply innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in the T2D population. It will use this knowledge to characterise clinical phenotypes based on retinal functional and structural characteristics and serum biomarkers in order to stratify the risk and severity of cognitive decline.

Alzheimer Europe contributed to the dissemination and exploitation (WP8) and communication activities (WP9) work packages. Alzheimer Europe was represented by Jean Georges and Angela Bradshaw. In 2020, they:

- Participated in General Assembly meetings and regular work package meetings
- Attended meetings of the Dissemination and Exploitation Board (DEB)
- Contributed to the development of the RECOGNISED communication plan
- Contributed to the production and maintenance of the communication tools (website, leaflet, twitter)
- Contributed to the efficient communication of the project via the Alzheimer Europe website, newsletter and events

RECOGNISED aims to determine the usefulness of the retina as a tool for identifying type 2 diabetes and cognitive impairment.
VirtualBrainCloud

The VirtualBrainCloud (TVB_Cloud) project was launched in December 2018 and will conclude at the end of 2022. TVB_Cloud will develop and validate a decision support system that provides access to high quality multi-disciplinary data for clinical practice. The result will be a cloud-based brain simulation platform to support personalised diagnostics and treatments for neurodegenerative diseases (NDD). The software will be tailored to the individual, bridging multiple scales to identify key mechanisms that predict NDD progression. The interdisciplinary VirtualBrainCloud consortium will also develop robust solutions for legal and ethical matters.

Alzheimer Europe contributed to the ethical and legal (work package 2) and communication and dissemination (work package 9) activities of TVB_Cloud. Alzheimer Europe was represented by Jean Georges and Angela Bradshaw. In 2020, they:

- Participated in quarterly General Assembly meetings and regular work package meetings
- Supported the organisation of a 1-day GDPR workshop: “Bridging the gap between new technologies, health research and the protection of personal data: GDPR impact”
- During this workshop, delivered a presentation on ethics and the patient perspective
- Organised two parallel sessions at the 30th Alzheimer Europe annual conference
- Co-developed and hosted a Virtual Booth at the 30th Alzheimer Europe annual conference
- Coordinated an article on the TVB_Cloud conference sessions for the Dementia in Europe magazine
- Co-hosted a Virtual Booth at the European Open Science Cloud EXPO
- Drafted and finalised D2.6 – Stakeholder conference report: specific issues of neurodegenerative disease: the patient’s perspective
- Contributed to the efficient communication of the project via the Alzheimer Europe website, newsletter and events

The VirtualBrainCloud project hosted sessions on AI, dementia and ethics at the online 30th Alzheimer Europe Conference, 20-22 October 2020
Support of European research activities

In addition to the projects described above, Alzheimer Europe played a minor role and supported a number of other European research projects.

ADAIR

ADAIR is a multi-national collaboration between neuroscientists, environmental scientists, clinicians, epidemiologists, informaticians, and non-profit organisations. Results from the project will be actively and regularly communicated to the scientific community, the public, the media, patient organisations and key governing bodies in Europe via scientific and non-scientific publications through traditional and digital media outlets, and via discussions with stakeholder groups. The ADAIR project is funded by the JPND, for a duration of 36 months and will conclude in December 2022.

In 2020:
• Executive Director Jean Georges attended the kick-off meeting in January.
• Project Officer Ana Diaz participated in the ADAIR project general assembly in June.
• Alzheimer Europe contributed to the project’s stakeholder analysis and communication strategy.

DISTINCT

DISTINCT (Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology) is an EU funded Marie Skłodowska-Curie Innovative Training Network which received continued funding in 2020. Coordinated by the University of Nottingham, the network brings together 13 research organisations which host 15 early-stage researchers who are focusing on improving the usability of technology in dementia care.

Alzheimer Europe and its European Working Group of People with Dementia were involved in this project and the organisation was represented by Dianne Gove and Ana Diaz in this project. In 2020, they:
• organised and participated, together with the Chair of the EWG-PWD, in an online session at the DISTINCT Winter school on public involvement
• organised and agreed on secondment plans for two early-stage researchers from DZNE (to start in 2021)
• contributed towards a consultation on the topic of Advance Care Planning with the members of the EWGPWD and one of ESRs from the project

The DISTINCT project’s 15 Early Career Researchers
OTHER ACTIVITIES AND PROJECTS

MIRIADE

MIRIADE (Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis) is another EU funded Marie Skłodowska-Curie Innovative Training Network which received continued funding in 2020. The project aims to generate a novel generation of scientists able to accelerate fluid biomarker development for dementias.

Alzheimer Europe’s role in the project was to support the dissemination and communication activities and provide secondments to two early-stage researchers during the course of the project. The organisation was represented by Jean Georges, Ana Diaz and Dianne Gove in this project. In 2020, they:

- attended online meetings
- organised an interactive virtual session during one of the training workshops with the Chair and Vice Chairs of the European Working Group of People with Dementia together with the early-stage researchers.

PRIME

The PRIME (Prevention and Remediation of Insulin Multimorbidity in Europe) brings together a multidisciplinary team to (1) extend our understanding of insulin multimorbidity across the lifespan, (2) understand the causal mechanisms linking somatic and mental insulin-related illnesses, (3) develop tools for early diagnosis, improved clinical care, and prevention of insulin-related lifespan multimorbidity. PRIME aims to bring this new knowledge to society, based on e.g. repurposing medication and lifestyle interventions (diet/exercise monitored by mHealth assessment), identifying and validating novel drug targets, developing and testing candidate biomarkers, and by improving existing medical guidelines and policy. Furthermore, educational approaches to inform clinicians, patients, and the general public will be developed.

SPAN+

The SPAN+ project, which is led by Radboud University Medical Centre, aims to develop an effective empowerment intervention for people with dementia at home and in care homes. Alzheimer Europe was represented by Dianne Gove and Ana Diaz in this project. In 2020, they continued to liaise with the SPAN+ researchers and to keep the EWGPWD updated on progress in the context of their ongoing involvement in this work.
Corporate affairs

European Parliament lunch debates/workshops

As a result of the COVID-19 pandemic, Alzheimer Europe only held one in-person European Parliament lunch debate in 2020:

- On 18 February 2020, Christophe Hansen, MEP (Luxembourg) chaired a European Parliament lunch debate on “The Innovative Medicines Initiative (IMI): Advancing Alzheimer’s research through private-public partnerships”. The meeting was co-hosted with the Neuronet Coordinated Support Action, with presentations from Carlos Diaz, Project Coordinator for the Neuronet project, Bart Vannieuwenhuyse, Co-Lead of the European Medical Information Framework (EMIF) project (2013 – 2017) and Pierre Meulien, Executive Director of IMI.
- On 9 December 2020, Sirpa Pietikäinen, MEP (Finland) chaired an online European Parliament Workshop on “Maintaining dementia as a public health and research priority during the COVID-19 pandemic”. The meeting heard presentations from Dianne Gove, Angela Bradshaw and Owen Miller, from Alzheimer Europe, as well as Isidro Laso Ballesteros, from the Cabinet of Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, and Stefan Schreck, Adviser to the European Commission Health & Food Safety Directorate General.

Both events were well-attended, with representatives from the European Parliament and Commission, AE member associations, national government, people with dementia and their carers, and the organisation’s sponsors, all in attendance.

MEPs attending Alzheimer Europe’s online European Parliament workshop, December 2020 (LtR: Sirpa Pietikainen (Finland), Marc Angel (Luxembourg) and Deirdre Clune (Ireland))

Speakers at Alzheimer Europe’s European Parliament lunch debate, Brussels, 18 February 2020
Dementia in Europe magazine

In 2020, Alzheimer Europe published three issues of the Dementia in Europe magazine, which included Alzheimer Europe’s activities, such as the lunch debates and workshop, as well as covering relevant developments at a European and national level which had relevance for dementia policy.

As a result of the COVID-19 pandemic, we took the decision to move the Dementia in Europe magazine to a digital-only format. As such, only the February 2020 edition was available as a printed copy.

Over the three editions of the magazine, we were pleased to have interviews and contributions from a number of European and national policy-makers, including:

- Deirdre Clune, MEP (Ireland)
- Franziska Giffey, Federal Minister for Family Affairs, Senior Citizens, Women and Youth (Germany)
- Christophe Hansen, MEP (Luxembourg)
- Sirpa Pietikäinen, MEP (Finland)
- Dubravka Šuica, EU Vice-President for Democracy and Demography
- Svandís Svavarsdóttir, Minister for Health (Iceland)
- Hilde Vautmans, MEP (Belgium)
- Adam Vojtech, Minister of Health (Czech Republic)

The 2020 issues included articles on a range of other relevant policy matters:

- New national dementia strategies in Germany, Iceland and Spain
- EU-funded research programmes into dementia (in which Alzheimer Europe was involved)
- EU developments in relation to the EU4Health programme, the Horizon Europe programme and the Multiannual Financial Framework (MFF)
- Meetings of the European Group of Governmental Experts on Dementia
- The impact of the COVID-19 pandemic on people with dementia and carers (including contributions from our EWGPWD)
- Activities of our national member organisations in campaigning and awareness raising
Clinical Trials Watch

In 2020, Alzheimer Europe continued with the development of its Clinical Trials Watch which provides accessible and up-to-date information on clinical trials that are investigating drugs for Alzheimer’s disease and other types of dementia. In 2020, Alzheimer Europe focused on clinical trials that were:

- Recruiting participants
- Conducted in at least one European country
- In phase II or phase III.

At the end of 2020, 8 phase II and 6 phase III clinical trials recruiting participants in Europe were included on the AE website.

Policy report “Dementia as a European Priority”

On 9 December 2020 Alzheimer Europe launched a new report, “Dementia as a European Priority – A Policy Overview”, examining past EU policies and initiatives on dementia and setting out recommendations for future priorities across Europe. The report was developed in the context of the negotiations which were taking place within the European Union in relation to the Multiannual Financial Framework (MFF), the EU4Health programme and the Horizon Europe research programme.

The report aimed to provide an overarching and high-level overview of the current policy context in relation to dementia, examining the most relevant and high-profile actions of recent years, reflecting:

- The work of Alzheimer Europe and the European Dementia Movement
- Different actions and initiatives of the EU
- Progress and ongoing challenges made at a national level
- The outstanding challenges that must be addressed

In the report, Alzheimer Europe sets out the position of dementia as a political priority in Europe in recent years, looking at political support for raising the profile of dementia, including different levels of support within the European Commission, Council and Parliament. Within the report, questions asked by Members of the European Parliament, conclusions and events hosted as part of the activities of the rotating Presidency of the EU, as well as an overview of key areas of work funded by the EU, are all set out to illustrate the progress which has been made over the past decade.

At a national level, the progress in the number of national countries developing and implementing national dementia strategies is also included, showing a considerable increase in the number of countries with such policies in place. Additionally, the document provides a brief overview of some of the work in which Alzheimer Europe has been engaged in recent years, such as the key activities in campaigning for change (including the Paris and Glasgow Declarations from 2006 and 2014), supporting and facilitating networks for sharing information and good practice (e.g. European Group of Governmental Experts on Dementia), as well as the generation of knowledge through our reports and publications.

Despite the demonstrable progress in recent years, the report highlights that people living with dementia continue to face a number of challenges, particularly in relation to the diagnosis and management of the condition, alongside the continued stigma associated with the disease. Wider societal challenges are also identified, including the increasing prevalence of dementia (which is estimated to double by 2050) and the economic cost of dementia to countries.

As a result, the report sets out a number of recommendations for the EU, outlining specific areas in which dementia should be prioritised across international, health, research and social policy. These include:

- Prioritising dementia research in EU Research Programmes (including Horizon Europe), providing a fair allocation of resources and funding for existing programmes and better coordination between programmes
- Prioritising dementia within policies relating to chronic diseases, mental health and ageing, both at an EU and national level
- Supporting Member States to work towards the implementation of the World Health Organization’s Global Action Plan on Dementia 2017–2025
- Recognising dementia as a disability and including dementia in disability policies.
OTHER ACTIVITIES AND PROJECTS

Data sharing initiative

Thanks to an educational grant from Gates Ventures, Alzheimer Europe started a mapping exercise of European research projects (with a focus on their data sharing practices) in May 2019. The aim of the project is to understand the legal framework, the facilitators and barriers to data sharing, as well as the perceptions of scientists, research participants and the general public towards data sharing and develop recommendations for policy makers.

This project is coordinated by Angela Bradshaw and Owen Miller. In 2020, they:

• Organised and moderated an Alzheimer’s Association Academy workshop on data sharing
• Performed a mapping exercise of Horizon 2020-funded dementia research projects
• Attended regular meetings and workshops of the “DataSavesLives” initiative (a multi-stakeholder initiative aimed at raising wider patient and public awareness of health data)
• Updated Gates Ventures on the progress of the exercise in teleconference meetings with Gates Ventures team members
• Disseminated updates on the project and relevant news via the Alzheimer Europe website and newsletter

“We could enable faster progress on all fronts of the Alzheimer’s fight by facilitating more data-sharing. Scientists all around the world are working hard to generate new discoveries every day. The data they’re collecting in the process are a tremendously powerful tool that can be harnessed better to understand and reduce the impact of the disease.”

Bill Gates
# Annex 1: 2020 Meetings

Meetings organised by AE in the framework of the 2020 Operating Grant

<table>
<thead>
<tr>
<th>Date</th>
<th>Meeting</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>17–18 February</td>
<td>AE Board</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>18–20 February</td>
<td>European Working Group of People with Dementia</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>19 February</td>
<td>AE Public Affairs meeting</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>24 March</td>
<td>Meeting of the European Governmental Expert Group on Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>27 March</td>
<td>AE intercultural care and support expert working group</td>
<td>Online</td>
</tr>
<tr>
<td>2 April</td>
<td>COVID-19 coping meeting with Alzheimer Europe members</td>
<td>Online</td>
</tr>
<tr>
<td>15 April</td>
<td>European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>7 May</td>
<td>AE Public Affairs meeting</td>
<td>Online</td>
</tr>
<tr>
<td>4 June</td>
<td>Meeting of the European Governmental Expert Group on Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>8 June</td>
<td>AE Board</td>
<td>Online</td>
</tr>
<tr>
<td>10 June</td>
<td>AE Public Affairs meeting</td>
<td>Online</td>
</tr>
<tr>
<td>11 June</td>
<td>European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>7–10 July</td>
<td>European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>11 August</td>
<td>Meeting with the Executive of the European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>8 September</td>
<td>Meeting with Alzheimer Switzerland to say farewell to the Swiss representative of the European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>30 September</td>
<td>AE Board</td>
<td>Online</td>
</tr>
<tr>
<td>5 October</td>
<td>AE Annual General Meeting</td>
<td>Online</td>
</tr>
<tr>
<td>7 October</td>
<td>European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>12 October</td>
<td>European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>16, 19 &amp; 20 October</td>
<td>Networking event for 30AEC delegates with dementia</td>
<td>Online</td>
</tr>
<tr>
<td>20–22 October</td>
<td>AE Conference “Dementia in a changing world”</td>
<td>Online</td>
</tr>
<tr>
<td>23 October</td>
<td>European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>10 November</td>
<td>Alzheimer’s Association Academy meeting</td>
<td>Online</td>
</tr>
<tr>
<td>24 November</td>
<td>Alzheimer’s Association Academy meeting</td>
<td>Online</td>
</tr>
<tr>
<td>1 December</td>
<td>Alzheimer’s Association Academy meeting</td>
<td>Online</td>
</tr>
<tr>
<td>7 December</td>
<td>AE Board</td>
<td>Online</td>
</tr>
<tr>
<td>7 December</td>
<td>Alzheimer’s Association Academy meeting</td>
<td>Online</td>
</tr>
<tr>
<td>8 December</td>
<td>Meeting of the European Group of Governmental Experts on Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>10 December</td>
<td>Executive meeting of the European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>11 December</td>
<td>Second Alzheimer Europe Ethics working group meeting</td>
<td>Online</td>
</tr>
<tr>
<td>14 December</td>
<td>European Working Group of People with Dementia</td>
<td>Online</td>
</tr>
<tr>
<td>17 December</td>
<td>European Working Group of People with Dementia Christmas gathering</td>
<td>Online</td>
</tr>
</tbody>
</table>
## Meetings attended by Alzheimer Europe representatives in the framework of the 2020 Operating Grant

<table>
<thead>
<tr>
<th>Date</th>
<th>Meeting</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 January</td>
<td>Meeting with Alzheimer Belgique</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>27 January</td>
<td>Meeting with France Alzheimer</td>
<td>Paris, France</td>
</tr>
<tr>
<td>12 February</td>
<td>Ethics Committee meeting of the Luxembourg Alzheimer’s Association</td>
<td>Luxembourg, Luxembourg</td>
</tr>
<tr>
<td>3–4 March</td>
<td>Meeting of the Patients’ and Consumers' Working Party of the EMA</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>6 April</td>
<td>WHO webinar</td>
<td>Online</td>
</tr>
<tr>
<td>10 April</td>
<td>European Disability Forum’s (EDF) meeting on COVID-19</td>
<td>Online</td>
</tr>
<tr>
<td>25 April</td>
<td>General Assembly of the European Patients’ Forum (EPF)</td>
<td>Online</td>
</tr>
<tr>
<td>4–5 May</td>
<td>European Patients’ Forum (EPF) consultation webinars</td>
<td>Online</td>
</tr>
<tr>
<td>7 May</td>
<td>Meeting of the Core Group of the EU4Health campaign</td>
<td>Online</td>
</tr>
<tr>
<td>8 May</td>
<td>European Disability Forum’s (EDF) webinar</td>
<td>Online</td>
</tr>
<tr>
<td>20 May</td>
<td>European Disability Forum’s (EDF) meeting</td>
<td>Online</td>
</tr>
<tr>
<td>27 May</td>
<td>Mental Health Europe (MHE) webinar</td>
<td>Online</td>
</tr>
<tr>
<td>29 May</td>
<td>Meeting of the Core Group of the EU4Health campaign</td>
<td>Online</td>
</tr>
<tr>
<td>2 June</td>
<td>Meeting of the Patients’ and Consumers’ Working Party of the EMA</td>
<td>Online</td>
</tr>
<tr>
<td>11 June</td>
<td>Online engagement session for EU4Health campaign</td>
<td>Online</td>
</tr>
<tr>
<td>25 June</td>
<td>Patient Access Partnership and DG SANTE meeting</td>
<td>Online</td>
</tr>
<tr>
<td>26 June</td>
<td>WHO briefing</td>
<td>Online</td>
</tr>
<tr>
<td>1 July</td>
<td>COVID-19 and mental health platform meeting</td>
<td>Online</td>
</tr>
<tr>
<td>7 July</td>
<td>Core Group of the EU4Health coalition meeting</td>
<td>Online</td>
</tr>
<tr>
<td>13 July</td>
<td>Scientific Panel for Health webinar</td>
<td>Online</td>
</tr>
<tr>
<td>15 July</td>
<td>Meeting to relaunch the MEP Alliance on Mental Health</td>
<td>Online</td>
</tr>
<tr>
<td>28 July</td>
<td>European Patients’ Forum (EPF) webinar</td>
<td>Online</td>
</tr>
<tr>
<td>6 August</td>
<td>Meeting with WHO</td>
<td>Online</td>
</tr>
<tr>
<td>16 September</td>
<td>Meeting with members of Alzheimer Portugal</td>
<td>Online</td>
</tr>
<tr>
<td>17 September</td>
<td>Incisive Health meeting</td>
<td>Online</td>
</tr>
<tr>
<td>17 September</td>
<td>European Disability Forum’s (EDF) Group of European Non-Government Organisations</td>
<td>Online</td>
</tr>
<tr>
<td>23 September</td>
<td>European Medicines’ Agency (EMA) workshop</td>
<td>Online</td>
</tr>
<tr>
<td>15 October</td>
<td>Hearing Health Forum EU workshop</td>
<td>Online</td>
</tr>
<tr>
<td>23 October</td>
<td>EMA virtual training session</td>
<td>Online</td>
</tr>
<tr>
<td>26 October</td>
<td>EU Health Coalition summit</td>
<td>Online</td>
</tr>
<tr>
<td>26 October</td>
<td>Meeting with WHO</td>
<td>Online</td>
</tr>
<tr>
<td>26 October</td>
<td>EU Health Coalition summit</td>
<td>Online</td>
</tr>
<tr>
<td>26 October</td>
<td>France Alzheimer and the French Table Tennis Federation meeting</td>
<td>Online</td>
</tr>
<tr>
<td>3 November</td>
<td>EU4Health Civil Society Alliance meeting</td>
<td>Online</td>
</tr>
<tr>
<td>16 November</td>
<td>Patients and Consumers Working Party (PCWP) of the EMA meeting</td>
<td>Online</td>
</tr>
<tr>
<td>3 December</td>
<td>WHO meeting</td>
<td>Online</td>
</tr>
<tr>
<td>15 December</td>
<td>European Medicines’ Agency (EMA) EU Big Data Stakeholder Forum</td>
<td>Online</td>
</tr>
</tbody>
</table>
Other meetings organised by Alzheimer Europe or attended by Alzheimer Europe representatives in 2020

<table>
<thead>
<tr>
<th>Date</th>
<th>Meeting</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 February</td>
<td>PARADIGM project meeting</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>13–15 January</td>
<td>PRIME project meeting</td>
<td>Frankfurt, Germany</td>
</tr>
<tr>
<td>15–16 January</td>
<td>ADAIR project meeting</td>
<td>Prague, Czech Republic</td>
</tr>
<tr>
<td>20 January</td>
<td>DataSavesLives meeting</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>21 January</td>
<td>EFPIA task force meeting</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>27 January</td>
<td>RECOGNISED project launch</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>28 January</td>
<td>Neuronet project, Scientific Coordination Board meeting</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>4 February</td>
<td>EPAD project Change Management Team meeting</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>10 February</td>
<td>PARADIGM project meeting</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>18 February</td>
<td>Neuronet project consortium meeting</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>18 February</td>
<td>Alzheimer Europe Lunch Debate</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>18 February</td>
<td>Alzheimer Europe Company Round table</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>18 February</td>
<td>Biogen information meeting</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>20 February</td>
<td>EPAD project Investigators meeting</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>26 February</td>
<td>Neuronet project meeting</td>
<td>Diegem, Belgium</td>
</tr>
<tr>
<td>4 March</td>
<td>RADAR-AD project annual meeting</td>
<td>Online</td>
</tr>
<tr>
<td>11 March</td>
<td>EURO-FINGERS project kick-off meeting</td>
<td>Online</td>
</tr>
<tr>
<td>16 March</td>
<td>PREFER-PARADIGM project webinar</td>
<td>Online</td>
</tr>
<tr>
<td>16 March</td>
<td>AD Detect &amp; Prevent project steering committee meeting</td>
<td>Online</td>
</tr>
<tr>
<td>17 March</td>
<td>RECOGNISED project Dissemination and Exploitation Board meeting</td>
<td>Online</td>
</tr>
<tr>
<td>24 March</td>
<td>Judging Panel for the AAL Smart Ageing Prize</td>
<td>Online</td>
</tr>
<tr>
<td>31 March</td>
<td>PREFER-PARADIGM project workshop</td>
<td>Online</td>
</tr>
<tr>
<td>31 March</td>
<td>Meeting of the dementia panel of the European Academy of Neurology</td>
<td>Online</td>
</tr>
<tr>
<td>1–2 April</td>
<td>PARADIGM project workshop</td>
<td>Online</td>
</tr>
<tr>
<td>6 April</td>
<td>Exchange with Sodexo Europe</td>
<td>Online</td>
</tr>
<tr>
<td>15–16 April</td>
<td>International Congress and Convention Association (ICCA) webinar</td>
<td>Online</td>
</tr>
<tr>
<td>21–22 April</td>
<td>PARADIGM project workshop</td>
<td>Online</td>
</tr>
<tr>
<td>28 April</td>
<td>International Congress and Convention Association (ICCA) webinar</td>
<td>Online</td>
</tr>
<tr>
<td>29–30 April</td>
<td>General assembly meeting VirtualBrainCloud project</td>
<td>Online</td>
</tr>
<tr>
<td>5 May</td>
<td>Health First Europe webinar</td>
<td>Online</td>
</tr>
<tr>
<td>11 May</td>
<td>European Academy of Neurology and the European Alzheimer’s Disease Consortium meeting</td>
<td>Online</td>
</tr>
<tr>
<td>12 May</td>
<td>Health Advisory Board of GSK meeting</td>
<td>Online</td>
</tr>
<tr>
<td>12 May</td>
<td>PARADIGM project workshop</td>
<td>Online</td>
</tr>
<tr>
<td>13 May</td>
<td>DataSavesLives meeting</td>
<td>Online</td>
</tr>
<tr>
<td>14 May</td>
<td>VirtualBrainCloud project webinar</td>
<td>Online</td>
</tr>
<tr>
<td>14 May</td>
<td>EPAD project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>14 May</td>
<td>AD/ADR Funder Consortium meeting convened by the US Alzheimer’s Association</td>
<td>Online</td>
</tr>
<tr>
<td>15 May</td>
<td>Biogen AD Advocacy Steering Committee meeting</td>
<td>Online</td>
</tr>
<tr>
<td>Date</td>
<td>Meeting</td>
<td>Venue</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>18 May</td>
<td>Roche scientific Advisory Board meeting</td>
<td>Online</td>
</tr>
<tr>
<td>18 May</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>19 May</td>
<td>EFPIA webinar</td>
<td>Online</td>
</tr>
<tr>
<td>23 May</td>
<td>Dementia Panel of the European Academy of Neurology (EAN)</td>
<td>Online</td>
</tr>
<tr>
<td>23 May</td>
<td>IPA and INTERDEM webinar</td>
<td>Online</td>
</tr>
<tr>
<td>23–26 May</td>
<td>European Academy of Neurology (EAN) Conference</td>
<td>Online</td>
</tr>
<tr>
<td>25 May</td>
<td>Roche Scientific Advisory Board meeting</td>
<td>Online</td>
</tr>
<tr>
<td>25 May</td>
<td>SoCaTel Advisory Board meeting</td>
<td>Online</td>
</tr>
<tr>
<td>26 May</td>
<td>PRODEMOS project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>28 May</td>
<td>EURO-FINGERS project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>3 June</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>4 June</td>
<td>DataSavesLives tweet chat</td>
<td>Online</td>
</tr>
<tr>
<td>5 June</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>9 June</td>
<td>AE Company Round table</td>
<td>Online</td>
</tr>
<tr>
<td>9 June</td>
<td>ADAIR project general assembly</td>
<td>Online</td>
</tr>
<tr>
<td>11 June</td>
<td>Roche workshop</td>
<td>Online</td>
</tr>
<tr>
<td>12 June</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>15–16 June</td>
<td>Workshop by University Hospital of Geneva</td>
<td>Online</td>
</tr>
<tr>
<td>17 June</td>
<td>European Alzheimer’s Disease Consortium and the European Academy of Neurology meeting</td>
<td>Online</td>
</tr>
<tr>
<td>18 June</td>
<td>Biogen webinar</td>
<td>Online</td>
</tr>
<tr>
<td>19 June</td>
<td>RECOGNISED project webinar</td>
<td>Online</td>
</tr>
<tr>
<td>23 June</td>
<td>AD-Detect-Prevent project webinar</td>
<td>Online</td>
</tr>
<tr>
<td>25–26 June</td>
<td>PARADIGM project Open Forum</td>
<td>Online</td>
</tr>
<tr>
<td>29–30 June</td>
<td>PRODEMOS project general assembly meeting</td>
<td>Online</td>
</tr>
<tr>
<td>30 June</td>
<td>Science</td>
<td>Business web conference</td>
</tr>
<tr>
<td>30 June</td>
<td>European Federation of Neurological Associations (EFNA) webinar</td>
<td>Online</td>
</tr>
<tr>
<td>1 July</td>
<td>DataSavesLives meeting</td>
<td>Online</td>
</tr>
<tr>
<td>9 July</td>
<td>ADAIR project leadership meeting</td>
<td>Online</td>
</tr>
<tr>
<td>9 July</td>
<td>PARADIGM project online Patient Engagement Open Forum</td>
<td>Online</td>
</tr>
<tr>
<td>10 July</td>
<td>Meeting with Roche</td>
<td>Online</td>
</tr>
<tr>
<td>14 July</td>
<td>EFPIA webinar</td>
<td>Online</td>
</tr>
<tr>
<td>16 July</td>
<td>VirtualBrainCloud project interim review</td>
<td>Online</td>
</tr>
<tr>
<td>22–24 July</td>
<td>Biogen Advocacy Steering Committee</td>
<td>Online</td>
</tr>
<tr>
<td>23 July</td>
<td>WW-FINGERS Network meeting</td>
<td>Online</td>
</tr>
<tr>
<td>27–31 July</td>
<td>Alzheimer’s Association International Conference (AAIC)</td>
<td>Online</td>
</tr>
<tr>
<td>29 July</td>
<td>Meeting with company “Brainstorm”</td>
<td>Online</td>
</tr>
<tr>
<td>29 July</td>
<td>World Dementia Council meeting</td>
<td>Online</td>
</tr>
<tr>
<td>30 July</td>
<td>Biogen webinar</td>
<td>Online</td>
</tr>
<tr>
<td>4 August</td>
<td>JPI stakeholder workshop</td>
<td>Online</td>
</tr>
<tr>
<td>5 August</td>
<td>Call with TauRx</td>
<td>Online</td>
</tr>
<tr>
<td>12 August</td>
<td>Meeting with Pfizer</td>
<td>Online</td>
</tr>
<tr>
<td>13 August</td>
<td>Centre for Dementia Prevention and Alzheimer Scotland webinar</td>
<td>Online</td>
</tr>
<tr>
<td>Date</td>
<td>Meeting</td>
<td>Venue</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>26 August</td>
<td>DISTINCT project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>2 September</td>
<td>Meeting with Gates Ventures</td>
<td>Online</td>
</tr>
<tr>
<td>7 September</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>9 September</td>
<td>RADAR-AD project PAB meeting</td>
<td>Online</td>
</tr>
<tr>
<td>10 September</td>
<td>Information meeting with TauRx</td>
<td>Online</td>
</tr>
<tr>
<td>15 September</td>
<td>Meeting with Brain Health Scotland</td>
<td>Online</td>
</tr>
<tr>
<td>18 September</td>
<td>VirtualBrainCloud project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>21 September</td>
<td>PAVE project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>23 September</td>
<td>EEPO Global Webinar</td>
<td>Online</td>
</tr>
<tr>
<td>24 September</td>
<td>Biogen Expert Panel</td>
<td>Online</td>
</tr>
<tr>
<td>28 September</td>
<td>EFID webinar</td>
<td>Online</td>
</tr>
<tr>
<td>28 September</td>
<td>European Foundation Initiative on Dementia meeting</td>
<td>Online</td>
</tr>
<tr>
<td>29 September</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>30 September-1 October</td>
<td>EPAD project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>1 October</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>2 October</td>
<td>Judging panel for the AAL Smart Ageing Prize</td>
<td>Online</td>
</tr>
<tr>
<td>2 October</td>
<td>Mental Health Europe webinar</td>
<td>Online</td>
</tr>
<tr>
<td>6 October</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>6 October</td>
<td>VirtualBrainCloud project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>8–9 October</td>
<td>AMYPAD project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>13 October</td>
<td>Patients BioForum hosted by EuropaBio</td>
<td>Online</td>
</tr>
<tr>
<td>15 October</td>
<td>PARADIGM PEOF session</td>
<td>Online</td>
</tr>
<tr>
<td>16 October</td>
<td>INTERDEM taskforce meeting</td>
<td>Online</td>
</tr>
<tr>
<td>26 October</td>
<td>PARADIGM project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>27 October</td>
<td>PRODEMOS project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>29 October</td>
<td>Language and communication in multilingual speakers with dementia project closing meeting</td>
<td>Online</td>
</tr>
<tr>
<td>2–3 November</td>
<td>International Congress and Convention Association (ICCA) Congress</td>
<td>Online</td>
</tr>
<tr>
<td>4 November</td>
<td>International Congress and Convention Association (ICCA) BeNeLux Chapter meeting</td>
<td>Online</td>
</tr>
<tr>
<td>5 November</td>
<td>Meeting with the Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)</td>
<td>Online</td>
</tr>
<tr>
<td>5 November</td>
<td>PARADIGM Patient Engagement Open Forum (PEOF)</td>
<td>Online</td>
</tr>
<tr>
<td>5 November</td>
<td>DISTINCT project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>9 November</td>
<td>PRIME project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>9,16 &amp; 20 November</td>
<td>PARADIGM project Q&amp;A sessions</td>
<td>Online</td>
</tr>
<tr>
<td>12 November</td>
<td>Neuronet project Task Force meeting</td>
<td>Online</td>
</tr>
<tr>
<td>12 November</td>
<td>MIRIADE project training days</td>
<td>Online</td>
</tr>
<tr>
<td>13 November</td>
<td>Biogen Europe meeting</td>
<td>Online</td>
</tr>
<tr>
<td>16 November</td>
<td>Meeting with Global Alzheimer’s Platform</td>
<td>Online</td>
</tr>
<tr>
<td>17 November</td>
<td>European Open Science Cloud forum</td>
<td>Online</td>
</tr>
<tr>
<td>17 November</td>
<td>Information meeting by Nutricia</td>
<td>Online</td>
</tr>
<tr>
<td>18 November</td>
<td>IEEPO2020 Virtual World Café</td>
<td>Online</td>
</tr>
<tr>
<td>18 November</td>
<td>Patients BioForum Patient Think Tank</td>
<td>Online</td>
</tr>
<tr>
<td>Date</td>
<td>Meeting</td>
<td>Venue</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>18 November</td>
<td>DISTINCT project consultation with EWGPWD</td>
<td>Online</td>
</tr>
<tr>
<td>18–19 November</td>
<td>BestCities Global Forum 2020</td>
<td>Online</td>
</tr>
<tr>
<td>19 November</td>
<td>EuroHealthNet workshop</td>
<td>Online</td>
</tr>
<tr>
<td>19 November</td>
<td>VirtualBrainCloud meeting</td>
<td>Online</td>
</tr>
<tr>
<td>19 November</td>
<td>MIRIADE project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>19 November</td>
<td>Meeting with Jonathan de Jong &amp; Teun Toebes</td>
<td>Online</td>
</tr>
<tr>
<td>20 November</td>
<td>Neuronet project Task Force meeting</td>
<td>Online</td>
</tr>
<tr>
<td>20 November</td>
<td>Biogen Advisory Committee meeting</td>
<td>Online</td>
</tr>
<tr>
<td>23 November</td>
<td>PARADIGM project farewell ceremony</td>
<td>Online</td>
</tr>
<tr>
<td>23 November</td>
<td>Patient Engagement Open Forum (PEOF)</td>
<td>Online</td>
</tr>
<tr>
<td>24 November</td>
<td>Biogen Advisory Committee meeting</td>
<td>Online</td>
</tr>
<tr>
<td>25 November</td>
<td>Meeting with Roche</td>
<td>Online</td>
</tr>
<tr>
<td>27 November</td>
<td>RADAR-AD project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>27 November</td>
<td>European Academy of Neurology (EAN) and the European Federation of Neurological Associations (EFNA) meeting</td>
<td>Online</td>
</tr>
<tr>
<td>30 November</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>1 December</td>
<td>Management Team meeting of the Dementia Panel of the European Academy of Neurology</td>
<td>Online</td>
</tr>
<tr>
<td>2 December</td>
<td>RADAR-AD project Patient Advisory Board meeting</td>
<td>Online</td>
</tr>
<tr>
<td>2–4 December</td>
<td>Lausanne VII meeting</td>
<td>Online</td>
</tr>
<tr>
<td>3 December</td>
<td>EU Convention Bureaux Network</td>
<td>Online</td>
</tr>
<tr>
<td>7 December</td>
<td>Guest lecture at University of Vechta</td>
<td>Online</td>
</tr>
<tr>
<td>9 December</td>
<td>European Parliament Workshop</td>
<td>Online</td>
</tr>
<tr>
<td>9 December</td>
<td>AE Company Round table</td>
<td>Online</td>
</tr>
<tr>
<td>10 December</td>
<td>Meeting with EFPIA Alzheimer’s team</td>
<td>Online</td>
</tr>
<tr>
<td>10 December</td>
<td>International Congress and Convention Association (ICCA) Workshop</td>
<td>Online</td>
</tr>
<tr>
<td>11 December</td>
<td>Health Advisory Board meeting of GSK</td>
<td>Online</td>
</tr>
<tr>
<td>11 December</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>14 December</td>
<td>Meeting with Essity</td>
<td>Online</td>
</tr>
<tr>
<td>14 December</td>
<td>EURO-FINGERS project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>17 December</td>
<td>Neuronet project meeting</td>
<td>Online</td>
</tr>
<tr>
<td>18 December</td>
<td>ADDIA project meeting</td>
<td>Online</td>
</tr>
</tbody>
</table>
Annex 2: Scientific publications published in 2020

In 2020, Alzheimer Europe staff contributed to the following scientific publications:


My first report as the Honorary Treasurer of Alzheimer Europe looks back on a particularly challenging year. As a lot of organisations and associations, Alzheimer Europe was of course affected by the ongoing COVID-19 pandemic. As highlighted in our Annual Report though, the activities and meetings were kept at a high level and the organisation was able to meet almost all objectives set out in its initial Work Plan.

On a financial side, our 2020 income was a bit more than EUR 300K under budget and close to EUR 650K below our 2019 income. The biggest hits to our income were the reduced EU operating grant and project funding and much lower than expected conference registrations, since our Annual Conference went virtual last year. On the plus side, we were able to exceed our budgeted income from our corporate sponsors.
All supporters and funders of Alzheimer Europe are acknowledged on page 53 of this report, but I would really like to single out the invaluable support we have received from the European health programme in the form of an operating grant to cover our core activities, as well as the very generous grant of EUR 88K provided by Fondation Alzheimer of Luxembourg.

Thankfully, the reduction in income was accompanied by an even bigger decrease in expenditure, principally due to the fact that all travel and face-to-face meetings, including our Annual Conference, were stopped from early March and all our publications were published as online versions only leading to significant savings in printing and mailing costs. Overall, the expenditure was close to EUR 460K below budget which allowed Alzheimer Europe to provide a grant of EUR 121K to the Alzheimer Europe Foundation and close the year with an operating surplus of EUR 35K.

2020 expenditure versus budget (€)

I am therefore particularly happy that the reserves of our association and those of the Alzheimer Europe Foundation have increased to EUR 472K and EUR 459K respectively representing close to 11 months of running costs. This will allow us to confront potential future difficulties, especially with regard to the continuity of the operating grant mechanism at EU level, with more confidence.

Let me close this short preface by expressing my thanks to the Alzheimer Europe team and especially our Finance Officer Stefanie Peulen and Executive Director Jean Georges, who paid very close attention to the impact of the COVID-19 pandemic on the organisation’s activities and finances and regularly updated the Board and me with updated financial reports and forecasts. All in all, the organisation was able to keep good control over the financial affairs during this challenging year in the history of Alzheimer Europe.

Marco Blom
Honorary Treasurer
Report of the Réviseur d'entreprises agréé

ALZHEIMER EUROPE
Association sans but lucratif

R.C.S. Luxembourg F 2773
14, rue Dicks
L-1417 LUXEMBOURG

Report of the Réviseur d’entreprises agréé and annual accounts as at December 31, 2020
To the Board of Directors of
ALZHEIMER EUROPE
14, rue Dicks
L-1417 LUXEMBOURG

REPORT OF THE REVISEUR D’ENTREPRISES AGREE

Opinion

We have audited the annual accounts of ALZHEIMER EUROPE (the « Association »), which comprise the balance sheet as at December 31, 2020, and profit and loss account for the year then ended, and notes to the annual accounts, including a summary of significant accounting policies.

In our opinion, the accompanying annual accounts give a true and fair view of the financial position of the Association as at December 31, 2020, and of the results of its operations for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the annual accounts.

Basis for opinion

We conducted our audit in accordance with the Law of the 23 July 2016 on the audit profession (Law of 23 July 2016) and with International Standards on Auditing (ISAs) as adopted for Luxembourg by the “Commission de Surveillance du Secteur Financier” (CSSF). Our responsibilities under the Law of 23 July 2016 and ISAs as adopted for Luxembourg by the CSSF are further described in the « Responsibilities of “reviseur d’entreprises agréé” for the Audit of the Annual Accounts » section of our report. We are also independent of the Association in accordance with the International Code of Ethics for Professional Accountants, including International Independence Standards, issued by the International Ethics Standards Board for Accountants (IESBA Code) as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the annual accounts, and have fulfilled our other ethical responsibilities under those ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Board of Directors of Those Charged with Governance for the annual accounts

The Board of Directors is responsible for the preparation and fair presentation of these annual accounts in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the annual accounts, and for such internal control as the Board of Directors determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.
In preparing the annual accounts, the Board of Directors is responsible for assessing the Association’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Association or to cease operations, or has no realistic alternative but to do so.

Responsibilities of the « Réviseur d’Entreprises Agréé » for the Audit of the annual accounts

Our objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue a report of "réviseur d’entreprises agréé" that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee than an audit conducted in accordance with the Law dated 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with the Law dated 23 July 2016, and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Association’s internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Association’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our report of "réviseur d’entreprises agréé" to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our report of "réviseur d’entreprises agréé". However, future events or conditions may cause the Association to cease to continue as a going concern.
• Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Luxembourg, February 22, 2021

For AUDITEURS ASSOCIES, Cabinet de révision agréé
30, boulevard Joseph II
L-1840 Luxembourg

Philippe SLENDZAK
Partner

Appendix:

• Annual accounts as at December 31\textsuperscript{st}, 2020
ALZHEIMER EUROPE  
Association sans but lucratif  
RCS Luxembourg F2773

Balance sheet as of December 31, 2020

<table>
<thead>
<tr>
<th>Notes</th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Fixed assets</td>
<td>3, 1, 4</td>
<td>15,177.16</td>
</tr>
<tr>
<td>II. Tangible fixed assets</td>
<td></td>
<td>15,177.16</td>
</tr>
<tr>
<td><strong>D. Current assets</strong></td>
<td></td>
<td>1,200,108.71</td>
</tr>
<tr>
<td>II. Receivables</td>
<td>3, 2, 5</td>
<td>228,540.75</td>
</tr>
<tr>
<td>a) becoming due and payable within one year</td>
<td></td>
<td>228,540.75</td>
</tr>
<tr>
<td><strong>IV. Cash at bank and on deposit</strong></td>
<td></td>
<td>1,031,567.96</td>
</tr>
<tr>
<td><strong>E. Prepayments and accruals</strong></td>
<td>3, 3, 8</td>
<td>102,869.86</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>1,382,146.76</strong></td>
</tr>
</tbody>
</table>

**LIABILITIES**

| A. Capital and reserves | | 472,495.64 | 437,000.49 |
| V. Results brought forward | | 437,000.49 | 407,017.92 |
| VI. Results for the financial year | | 35,495.15 | 29,982.57 |
| **B. Provisions** | 3, 4, 7 | 37,605.96 | 31,885.28 |
| C. Debts | 3, 5, 8 | 716,414.48 | 696,443.43 |
| a) becoming due and payable within one year | | 716,414.48 | 696,443.43 |
| **D. Deferred income** | 3, 6, 9 | 155,630.68 | 172,171.22 |
| | | **1,382,146.76** | **1,327,500.42** |

The accompanying notes are an integral part of these annual accounts.
# Profit and loss account

**Year ended December 31, 2020**

<table>
<thead>
<tr>
<th>Notes</th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Other operating income</td>
<td>3.7, 10</td>
<td>1,322,672.02</td>
</tr>
<tr>
<td>5. Other external charges</td>
<td>11</td>
<td>-356,690.01</td>
</tr>
<tr>
<td>6. Staff costs</td>
<td>12, 13</td>
<td>-762,893.77</td>
</tr>
<tr>
<td>a) Wages and salaries</td>
<td></td>
<td>-697,381.03</td>
</tr>
<tr>
<td>b) Social security costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>i) relating to pensions</td>
<td></td>
<td>-57,240.05</td>
</tr>
<tr>
<td>ii) other social security costs</td>
<td></td>
<td>-38,232.69</td>
</tr>
<tr>
<td>7. Value adjustments</td>
<td></td>
<td>-7,287.34</td>
</tr>
<tr>
<td>a) in respect of formation expenses and of tangible and intangible fixed assets</td>
<td></td>
<td>-7,287.34</td>
</tr>
<tr>
<td>8. Other operating expenses</td>
<td>14</td>
<td>-130,365.15</td>
</tr>
<tr>
<td>11. Other interest receivables and other financial income</td>
<td></td>
<td>0.00</td>
</tr>
<tr>
<td>b) other interest and financial income</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>35,495.15</strong></td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these annual accounts.
Association sans but lucratif  
RCS Luxembourg F2773  

Notes to the annual accounts as at December 31, 2020

NOTE 1. GENERAL

Alzheimer Europe ("the association") was established on 2 March 1992 and is organised under the laws of Luxembourg as a non profit association subject to the law of 21 April 1928, amended by the law of 4 March 1994 for an unlimited period. It is registered with Trade and Company Register of Luxembourg with the number F2773.

The registered office is established in the municipality of Luxembourg, Luxembourg. The financial year runs from 1 January to 31 December of each year.

Alzheimer Europe is a voluntary organisation whose purpose is to enhance the dignity, respect and self-determination of the person with dementia and his/her family and other supporters throughout the course of the disease and to improve the quality of life, the care and treatment of people with dementia, their families and their carers through collaboration amongst its members.

The membership of Alzheimer Europe consists of national organisations of and for people with dementia, their families and their carers. The association shall be non-political and without religious or philosophical affiliation.

NOTE 2. BASIS OF PREPARATION

The annual accounts have been prepared in accordance with generally accepted accounting principles and with the laws and regulations in force in the Grand-Duchy of Luxembourg.

The association has voluntarily adopted the accounting policies of the amended law of 19 December 2002.

NOTE 3. SIGNIFICANT ACCOUNTING POLICIES

3.1. Fixed assets

Fixed assets are valued at purchase price including the expenses incidental thereto. They are depreciated using the straight line method over their estimated useful lives:

<table>
<thead>
<tr>
<th>Asset Type</th>
<th>Useful Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software</td>
<td>3 years</td>
</tr>
<tr>
<td>Furniture</td>
<td>5 years</td>
</tr>
<tr>
<td>Computer equipment</td>
<td>3 years</td>
</tr>
<tr>
<td>Other fixtures</td>
<td>5 years</td>
</tr>
</tbody>
</table>

3.2. Receivables

Receivables are recorded at nominal value. They will be subject to value adjustments when the estimated realisable value is lower than the nominal value. These value adjustments are reversed if the reasons for which the value adjustments were made have ceased to apply.
Notes to the annual accounts as at December 31, 2020

3.3. Prepayments and accruals

Prepayments represent expenditure incurred during the financial year or earlier but relating to a subsequent financial year. Accruals will be made for income that has been earned, but not yet received or invoiced.

3.4. Provisions

Provisions will be set up if losses or debts are likely or certain to be occurred, but uncertain as to their amount or the date on which they will arise.

3.5. Debts

Creditors are recorded at their reimbursement value.

3.6. Deferred income

Deferred income represents amounts received or invoiced during the financial year or earlier, that will be booked to income in a subsequent financial year.

3.7. Co-financing in kind

Goods or services obtained at reduced rates or for free are recorded at the fair market value of the item received. Expertise from member organisations is valued at a standard daily rate. In-kind contributions are booked in a separate revenue account. The expense side of the transaction is recorded in its functional expense account.

3.8. Foreign currency translation

The association maintains its books, records and bank accounts in EUR. Transactions expressed in currencies other than EUR are translated at the exchange rate applied by the bank at the time of the payment. If this rate is not known at the time the accounts are established, the monetary assets and liabilities in foreign currency and the underlying revenues and expenses are valued at the exchange rate prevailing at the Balance Sheet date, and exchange gains or losses will be recorded in the Profit and Loss account at the moment of their realisation.
## NOTE 4. FIXED ASSETS

The movements for the year are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Software (EUR)</th>
<th>Furniture (EUR)</th>
<th>Computer equipment (EUR)</th>
<th>Other fixtures (EUR)</th>
<th>Total (EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross book value – opening balance</td>
<td>3,602.13</td>
<td>22,609.93</td>
<td>31,734.09</td>
<td>20,110.02</td>
<td>78,053.17</td>
</tr>
<tr>
<td>Additions for the year</td>
<td>-</td>
<td>-</td>
<td>18,360.81</td>
<td>-</td>
<td>18,360.81</td>
</tr>
<tr>
<td>Gross book value – closing balance</td>
<td>3,602.13</td>
<td>22,609.93</td>
<td>50,094.90</td>
<td>20,110.02</td>
<td>96,416.88</td>
</tr>
<tr>
<td>Accumulated value adjustments – opening balance</td>
<td>3,602.13</td>
<td>19,835.23</td>
<td>27,280.56</td>
<td>19,234.53</td>
<td>69,952.45</td>
</tr>
<tr>
<td>Allocations for the year</td>
<td>-</td>
<td>954.05</td>
<td>5,447.80</td>
<td>875.49</td>
<td>7,287.34</td>
</tr>
<tr>
<td>Accumulated value adjustments – closing balance</td>
<td>3,602.13</td>
<td>20,799.28</td>
<td>32,728.36</td>
<td>20,110.02</td>
<td>77,239.79</td>
</tr>
<tr>
<td>Net book value – closing balance</td>
<td>-</td>
<td>1,810.55</td>
<td>17,356.54</td>
<td>-</td>
<td>19,177.19</td>
</tr>
<tr>
<td>Net book value – opening balance</td>
<td>-</td>
<td>2,774.70</td>
<td>4,453.53</td>
<td>875.49</td>
<td>8,103.72</td>
</tr>
</tbody>
</table>
Association sans but lucratif  
RCS Luxembourg F2773  

Notes to the annual accounts as at December 31, 2020  

NOTE 5. RECEIVABLES  
Receivables consist of:  

<table>
<thead>
<tr>
<th></th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accruals for EU subsidies</td>
<td>127,482.48</td>
<td>193,763.20</td>
</tr>
<tr>
<td>Other receivables</td>
<td>101,078.27</td>
<td>145,382.63</td>
</tr>
<tr>
<td></td>
<td>228,560.75</td>
<td>339,145.83</td>
</tr>
</tbody>
</table>

NOTE 6. PREPAYMENTS AND ACCRUALS  
Prepayments and accruals can be broken down as follows:  

<table>
<thead>
<tr>
<th></th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepayments</td>
<td>86,585.26</td>
<td>82,917.87</td>
</tr>
<tr>
<td>Other accruals</td>
<td>102,860.86</td>
<td>87,161.54</td>
</tr>
</tbody>
</table>

NOTE 7. PROVISIONS  
Provisions are composed of:  

<table>
<thead>
<tr>
<th></th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provision for untaken holidays</td>
<td>26,953.67</td>
<td>22,560.37</td>
</tr>
<tr>
<td>Audit provision</td>
<td>8,775.00</td>
<td>7,605.00</td>
</tr>
<tr>
<td>Other debts</td>
<td>1,877.29</td>
<td>1,779.91</td>
</tr>
<tr>
<td></td>
<td>37,506.96</td>
<td>31,945.28</td>
</tr>
</tbody>
</table>

NOTE 8. DEBTS  
The amounts due and payable for debts are as follows:  

<table>
<thead>
<tr>
<th></th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU subsidies received on account</td>
<td>542,297.20</td>
<td>530,585.84</td>
</tr>
<tr>
<td>Trade creditors</td>
<td>136,553.00</td>
<td>114,647.96</td>
</tr>
<tr>
<td>Social security debts</td>
<td>20,134.10</td>
<td>20,038.08</td>
</tr>
<tr>
<td>Tax debts</td>
<td>17,430.18</td>
<td>19,003.51</td>
</tr>
<tr>
<td>Other debts</td>
<td>-</td>
<td>1,069.54</td>
</tr>
<tr>
<td></td>
<td>716,414.48</td>
<td>686,443.43</td>
</tr>
</tbody>
</table>
# Notes to the annual accounts as at December 31, 2020

## NOTE 9. DEFERRED INCOME

Deferred income consists of:

<table>
<thead>
<tr>
<th></th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsorship received on account</td>
<td>80,000.00</td>
<td>48,750.00</td>
</tr>
<tr>
<td>Project participation and other subsidies received on account</td>
<td>75,830.68</td>
<td>123,421.22</td>
</tr>
<tr>
<td></td>
<td>155,830.68</td>
<td>172,171.22</td>
</tr>
</tbody>
</table>

## NOTE 10. OTHER OPERATING INCOME

Other operating income is composed of:

<table>
<thead>
<tr>
<th></th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU Subsidy</td>
<td>703,368.76</td>
<td>870,620.38</td>
</tr>
<tr>
<td>Corporate sponsorship (*)</td>
<td>243,446.94</td>
<td>251,338.52</td>
</tr>
<tr>
<td>Project participation and other subsidies</td>
<td>127,059.41</td>
<td>321,375.73</td>
</tr>
<tr>
<td>Co-financing in kind</td>
<td>79,980.76</td>
<td>133,683.07</td>
</tr>
<tr>
<td>Membership fees and contributions</td>
<td>57,036.97</td>
<td>57,630.71</td>
</tr>
<tr>
<td>Deferred income</td>
<td>56,180.55</td>
<td>70,000.00</td>
</tr>
<tr>
<td>AE Conference registration fees</td>
<td>44,850.00</td>
<td>264,050.00</td>
</tr>
<tr>
<td>Donations</td>
<td>9,097.43</td>
<td>2,597.88</td>
</tr>
<tr>
<td>Other operating income</td>
<td>311.80</td>
<td>6,854.98</td>
</tr>
<tr>
<td>Publication sales and royalties</td>
<td>36.40</td>
<td>403.40</td>
</tr>
<tr>
<td>Sponsorship received on account</td>
<td>0.00</td>
<td>-58,461.22</td>
</tr>
<tr>
<td></td>
<td>1,322,072.02</td>
<td>1,869,999.43</td>
</tr>
</tbody>
</table>

(*) Corporate sponsorship is accepted by Alzheimer Europe in line with its internal rules and regulations to ensure the independence of the association. All funders and amounts are acknowledged in full transparency on the Alzheimer Europe website and in the annual reports.
Notes to the annual accounts as at December 31, 2020

NOTE 11. OTHER EXTERNAL CHARGES

Other external charges are composed of:

<table>
<thead>
<tr>
<th>Description</th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>External experts</td>
<td>140,733.20</td>
<td>223,483.17</td>
</tr>
<tr>
<td>Accommodation expenses</td>
<td>58,875.08</td>
<td>376,360.04</td>
</tr>
<tr>
<td>Office rent and associated costs</td>
<td>46,491.35</td>
<td>45,913.45</td>
</tr>
<tr>
<td>Publication and Information material</td>
<td>37,731.60</td>
<td>88,245.20</td>
</tr>
<tr>
<td>Communication costs</td>
<td>28,991.66</td>
<td>48,404.75</td>
</tr>
<tr>
<td>Travel expenses</td>
<td>22,003.16</td>
<td>113,510.90</td>
</tr>
<tr>
<td>Equipment and Leasing</td>
<td>8,995.41</td>
<td>48,084.75</td>
</tr>
<tr>
<td>Office stationery and related costs</td>
<td>6,058.32</td>
<td>5,257.65</td>
</tr>
<tr>
<td>Membership fees</td>
<td>4,038.01</td>
<td>4,120.00</td>
</tr>
<tr>
<td>Bank charges</td>
<td>1,441.07</td>
<td>5,242.82</td>
</tr>
<tr>
<td>Recruitment costs</td>
<td>1,164.15</td>
<td>2,328.30</td>
</tr>
<tr>
<td>Other costs</td>
<td>167.50</td>
<td>120.44</td>
</tr>
<tr>
<td></td>
<td>350,096.61</td>
<td>961,671.54</td>
</tr>
</tbody>
</table>

NOTE 12. STAFF

The association employed an average of 10 persons on a full time equivalent basis during the financial year (2019: 10), one Executive Director and 9 employees.

NOTE 13. REMUNERATION OF THE BOARD OF DIRECTORS

No compensation was paid to members of the Board of Directors in respect of their functions within the association in the period under review. Moreover, no advances or loans have been granted to the members of the Board.

NOTE 14. OTHER OPERATING EXPENSES

Other operating expenses can be broken down as follows:

<table>
<thead>
<tr>
<th>Description</th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software licenses</td>
<td>9,160.50</td>
<td>3,443.85</td>
</tr>
<tr>
<td>Grant to Alzheimer Europe Foundation</td>
<td>121,114.65</td>
<td>78,328.40</td>
</tr>
<tr>
<td></td>
<td>130,305.15</td>
<td>81,772.25</td>
</tr>
</tbody>
</table>

NOTE 15. OFF-BALANCE SHEET COMMITMENTS

As at December 31, 2020, the association had a rental guarantee of EUR 15,200 granted to the owner of the offices used by the association.
Association sans but lucratif
RCS Luxembourg F2773

Notes to the annual accounts as at December 31, 2020

NOTE 16. AUDIT FEES

Audit fees for the year under review amounted to EUR 11,700 (2019: EUR 7,605).

NOTE 17. RELATED-PARTY TRANSACTIONS

The following significant transactions with related parties have been entered into during the year under review.

<table>
<thead>
<tr>
<th>Transaction</th>
<th>2020 (Euro)</th>
<th>2019 (Euro)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant to Alzheimer Europe Foundation</td>
<td>121,114.65</td>
<td>78,325.40</td>
</tr>
<tr>
<td>Grant from Fondation Alzheimer</td>
<td>87,000.00</td>
<td>87,000.00</td>
</tr>
</tbody>
</table>
## Breakdown of income

<table>
<thead>
<tr>
<th>Funding source</th>
<th>Core funding received (2020)</th>
<th>As % of AE core income (2020)</th>
<th>Project funding received (2020)</th>
<th>As % of AE Project income (2020)</th>
<th>Total funding received (2020)</th>
<th>As % of AE total income (2020)</th>
<th>As % of AE total income (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche</td>
<td>20,000</td>
<td>2.97%</td>
<td>49,775</td>
<td>7.65%</td>
<td>69,775</td>
<td>5.28%</td>
<td>3.29%</td>
</tr>
<tr>
<td>Biogen</td>
<td>19,747</td>
<td>2.94%</td>
<td>20,525</td>
<td>3.16%</td>
<td>40,272</td>
<td>3.04%</td>
<td>1.58%</td>
</tr>
<tr>
<td>Eisai</td>
<td>0.00%</td>
<td></td>
<td>20,000</td>
<td>3.08%</td>
<td>20,000</td>
<td>1.51%</td>
<td>1.45%</td>
</tr>
<tr>
<td>Lilly</td>
<td>0.00%</td>
<td></td>
<td>20,000</td>
<td>3.08%</td>
<td>20,000</td>
<td>1.51%</td>
<td>1.06%</td>
</tr>
<tr>
<td>Deferred income</td>
<td>0.00%</td>
<td></td>
<td>12,000</td>
<td>1.85%</td>
<td>12,000</td>
<td>0.91%</td>
<td>1.06%</td>
</tr>
<tr>
<td>Janssen</td>
<td>0.00%</td>
<td></td>
<td>10,000</td>
<td>1.54%</td>
<td>10,000</td>
<td>0.76%</td>
<td>0.53%</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>0.00%</td>
<td></td>
<td>10,000</td>
<td>1.54%</td>
<td>10,000</td>
<td>0.76%</td>
<td>0.53%</td>
</tr>
<tr>
<td>Abbvie</td>
<td>0.00%</td>
<td></td>
<td>10,000</td>
<td>1.54%</td>
<td>10,000</td>
<td>0.76%</td>
<td>0.53%</td>
</tr>
<tr>
<td>Grifols</td>
<td>0.00%</td>
<td></td>
<td>10,000</td>
<td>1.54%</td>
<td>10,000</td>
<td>0.76%</td>
<td>0.00%</td>
</tr>
<tr>
<td>EFPIA</td>
<td>10,000</td>
<td>1.49%</td>
<td>10,000</td>
<td>1.49%</td>
<td>20,000</td>
<td>0.76%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Lundbeck</td>
<td>0.00%</td>
<td></td>
<td>5,000</td>
<td>0.77%</td>
<td>5,000</td>
<td>0.38%</td>
<td>0.53%</td>
</tr>
<tr>
<td>TaurX</td>
<td>0.00%</td>
<td></td>
<td>5,000</td>
<td>0.77%</td>
<td>5,000</td>
<td>0.38%</td>
<td>0.00%</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>0.00%</td>
<td></td>
<td>900</td>
<td>0.14%</td>
<td>900</td>
<td>0.07%</td>
<td>0.07%</td>
</tr>
<tr>
<td>Otsuka</td>
<td>0.00%</td>
<td></td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.00%</td>
<td>1.32%</td>
</tr>
<tr>
<td>Amgen</td>
<td>0.00%</td>
<td></td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.00%</td>
<td>1.32%</td>
</tr>
<tr>
<td>Sponsorship received on account</td>
<td>0.00%</td>
<td></td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.00%</td>
<td>-0.63%</td>
</tr>
<tr>
<td><strong>Sub-total: Pharmaceutical funding</strong></td>
<td><strong>49,747</strong></td>
<td><strong>7.40%</strong></td>
<td><strong>173,200</strong></td>
<td><strong>26.64%</strong></td>
<td><strong>222,947</strong></td>
<td><strong>16.86%</strong></td>
<td><strong>12.64%</strong></td>
</tr>
<tr>
<td>Nutricia</td>
<td>0.00%</td>
<td></td>
<td>22,500</td>
<td>3.46%</td>
<td>22,500</td>
<td>1.70%</td>
<td>0.53%</td>
</tr>
<tr>
<td>Essity</td>
<td>0.00%</td>
<td></td>
<td>10,000</td>
<td>1.54%</td>
<td>10,000</td>
<td>0.76%</td>
<td>0.55%</td>
</tr>
<tr>
<td>Microsoft</td>
<td>6,060</td>
<td>0.90%</td>
<td>6,060</td>
<td>0.00%</td>
<td>6,060</td>
<td>0.46%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Newsweaver</td>
<td>4,188</td>
<td>0.62%</td>
<td>4,188</td>
<td>0.00%</td>
<td>4,188</td>
<td>0.32%</td>
<td>0.22%</td>
</tr>
<tr>
<td>Fujirebio</td>
<td>2,500</td>
<td>0.37%</td>
<td>2,500</td>
<td>0.00%</td>
<td>2,500</td>
<td>0.19%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Hammond Care</td>
<td>0.00%</td>
<td></td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.11%</td>
</tr>
<tr>
<td><strong>Sub-total: Other corporate sources</strong></td>
<td><strong>12,748</strong></td>
<td><strong>1.90%</strong></td>
<td><strong>32,500</strong></td>
<td><strong>5.00%</strong></td>
<td><strong>45,248</strong></td>
<td><strong>3.42%</strong></td>
<td><strong>1.43%</strong></td>
</tr>
<tr>
<td><strong>Total: Corporate funding</strong></td>
<td>62,495</td>
<td><strong>9.29%</strong></td>
<td><strong>205,700</strong></td>
<td><strong>31.63%</strong></td>
<td><strong>268,195</strong></td>
<td><strong>20.28%</strong></td>
<td><strong>14.07%</strong></td>
</tr>
<tr>
<td>European Commission</td>
<td>335,078</td>
<td><strong>49.83%</strong></td>
<td><strong>345,867</strong></td>
<td><strong>53.19%</strong></td>
<td><strong>680,945</strong></td>
<td><strong>51.48%</strong></td>
<td><strong>46.06%</strong></td>
</tr>
<tr>
<td>Luxembourg National research Fund (FNR)</td>
<td>0.00%</td>
<td></td>
<td>22,423</td>
<td>3.45%</td>
<td>22,423</td>
<td>1.70%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Irish Ministry for Agriculture, Food and Marine</td>
<td>2,000</td>
<td>0.30%</td>
<td>2,000</td>
<td>0.00%</td>
<td>2,000</td>
<td>0.15%</td>
<td>0.11%</td>
</tr>
<tr>
<td>Municipality of The Hague</td>
<td>0.00%</td>
<td></td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.00%</td>
<td>1.32%</td>
</tr>
<tr>
<td>Scottish Government</td>
<td>0.00%</td>
<td></td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.00%</td>
<td>1.07%</td>
</tr>
<tr>
<td><strong>Total: Public funding</strong></td>
<td>337,078</td>
<td><strong>50.13%</strong></td>
<td><strong>368,290</strong></td>
<td><strong>56.64%</strong></td>
<td><strong>705,369</strong></td>
<td><strong>53.33%</strong></td>
<td><strong>48.56%</strong></td>
</tr>
<tr>
<td>Foundation Alzheimer, Luxembourg</td>
<td>87,000</td>
<td>12.94%</td>
<td>87,000</td>
<td>0.00%</td>
<td>87,000</td>
<td>6.58%</td>
<td>4.60%</td>
</tr>
<tr>
<td>Time donated by experts</td>
<td>47,100</td>
<td>7.00%</td>
<td>47,100</td>
<td>0.00%</td>
<td>47,100</td>
<td>3.56%</td>
<td>3.73%</td>
</tr>
<tr>
<td>Deferred income</td>
<td>0.00%</td>
<td></td>
<td>44,181</td>
<td>6.79%</td>
<td>44,181</td>
<td>3.34%</td>
<td>2.65%</td>
</tr>
<tr>
<td>Aridhia – EPAD</td>
<td>0.00%</td>
<td></td>
<td>10,943</td>
<td>1.68%</td>
<td>10,943</td>
<td>0.83%</td>
<td>0.00%</td>
</tr>
</tbody>
</table>
## Breakdown of income

<table>
<thead>
<tr>
<th>Funding source</th>
<th>Core funding received (2020)</th>
<th>As % of AE core income (2020)</th>
<th>Project funding received (2020)</th>
<th>As % of AE Project income (2020)</th>
<th>Total funding received (2020)</th>
<th>As % of AE total income (2020)</th>
<th>As % of AE total income (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Nottingham – DISTINCT</td>
<td>0.00%</td>
<td>5,000</td>
<td>0.77%</td>
<td>5,000</td>
<td>0.38%</td>
<td>0.06%</td>
<td></td>
</tr>
<tr>
<td>University of Eastern Finland – ADAIR</td>
<td>0.00%</td>
<td>5,000</td>
<td>0.77%</td>
<td>5,000</td>
<td>0.38%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td>University of Edinburgh – EPAD</td>
<td>0.00%</td>
<td>4,195</td>
<td>0.65%</td>
<td>4,195</td>
<td>0.32%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td>VUMC – MIRIAD</td>
<td>0.00%</td>
<td>3,215</td>
<td>0.49%</td>
<td>3,215</td>
<td>0.24%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td>Concentris- PRIME</td>
<td>0.00%</td>
<td>3,000</td>
<td>0.46%</td>
<td>3,000</td>
<td>0.23%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td>BBDiag</td>
<td>2,500</td>
<td>0.37%</td>
<td>0.00%</td>
<td>2,500</td>
<td>0.19%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td>PAVE</td>
<td>2,500</td>
<td>0.37%</td>
<td>0.00%</td>
<td>2,500</td>
<td>0.19%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td>Alzheimer Europe Foundation</td>
<td>1,723</td>
<td>0.26%</td>
<td>0.00%</td>
<td>1,723</td>
<td>0.13%</td>
<td>0.15%</td>
<td></td>
</tr>
<tr>
<td>DZNE</td>
<td>1,250</td>
<td>0.19%</td>
<td>0.00%</td>
<td>1,250</td>
<td>0.09%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td>University of Wolverhampton – MinD</td>
<td>0.00%</td>
<td>734</td>
<td>0.11%</td>
<td>734</td>
<td>0.06%</td>
<td>0.10%</td>
<td></td>
</tr>
<tr>
<td>Various organisations</td>
<td>481</td>
<td>0.07%</td>
<td>0.00%</td>
<td>481</td>
<td>0.04%</td>
<td>0.41%</td>
<td></td>
</tr>
<tr>
<td>Gates Ventures</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>4.80%</td>
<td></td>
</tr>
<tr>
<td>Robert Bosch Stiftung</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>2.65%</td>
<td></td>
</tr>
<tr>
<td>SPAN+</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>1.01%</td>
<td></td>
</tr>
<tr>
<td>Fundació ACE</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.29%</td>
<td></td>
</tr>
<tr>
<td>Deltaplan</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.20%</td>
<td></td>
</tr>
<tr>
<td>Qwiek</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.13%</td>
<td></td>
</tr>
<tr>
<td>ActiveCues</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.09%</td>
<td></td>
</tr>
<tr>
<td>Anglia Ruskin University</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.07%</td>
<td></td>
</tr>
<tr>
<td>University of Stirling</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.07%</td>
<td></td>
</tr>
<tr>
<td>CRDLT Maastricht</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.07%</td>
<td></td>
</tr>
<tr>
<td>De Beleef TV</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.07%</td>
<td></td>
</tr>
<tr>
<td>Joanneum Research</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.07%</td>
<td></td>
</tr>
<tr>
<td>Mindbytes BVBA</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.04%</td>
<td></td>
</tr>
<tr>
<td>McRoberts</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.04%</td>
<td></td>
</tr>
<tr>
<td>Alzheimer Centrum, Amsterdam</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Income received on account</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-</td>
<td>0.00%</td>
<td>-4.05%</td>
<td></td>
</tr>
<tr>
<td><strong>Total: Foundations and organisations</strong></td>
<td><strong>142,553</strong></td>
<td><strong>21.20%</strong></td>
<td><strong>76,267</strong></td>
<td><strong>11.73%</strong></td>
<td><strong>218,821</strong></td>
<td><strong>16.54%</strong></td>
<td><strong>17.25%</strong></td>
</tr>
<tr>
<td>Individuals (conference fees, donations, publication sales)</td>
<td>50,147</td>
<td>7.46%</td>
<td>0.00%</td>
<td>50,147</td>
<td>3.79%</td>
<td>14.02%</td>
<td></td>
</tr>
<tr>
<td><strong>Total: Individuals</strong></td>
<td><strong>50,147</strong></td>
<td><strong>7.46%</strong></td>
<td><strong>0</strong></td>
<td><strong>50,147</strong></td>
<td><strong>3.79%</strong></td>
<td><strong>14.02%</strong></td>
<td></td>
</tr>
<tr>
<td>AE member organisations</td>
<td>80,140</td>
<td>11.92%</td>
<td>0.00%</td>
<td>80,140</td>
<td>6.06%</td>
<td>6.09%</td>
<td></td>
</tr>
<tr>
<td><strong>Total: Member organisations</strong></td>
<td><strong>80,140</strong></td>
<td><strong>11.92%</strong></td>
<td><strong>0</strong></td>
<td><strong>80,140</strong></td>
<td><strong>6.06%</strong></td>
<td><strong>6.09%</strong></td>
<td></td>
</tr>
<tr>
<td>Bank interest and similar</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0</td>
<td>0.00%</td>
<td>0.00%</td>
<td></td>
</tr>
<tr>
<td><strong>Total: Bank interest and similar</strong></td>
<td><strong>0</strong></td>
<td><strong>0.00%</strong></td>
<td><strong>0</strong></td>
<td><strong>0</strong></td>
<td><strong>0.00%</strong></td>
<td><strong>0.00%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>672,414</strong></td>
<td><strong>100%</strong></td>
<td><strong>650,258</strong></td>
<td><strong>100%</strong></td>
<td><strong>1,322,672</strong></td>
<td><strong>100%</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>
Our sponsors and supporters
Alzheimer Europe Board

Members of the Alzheimer Europe Board (2020–2022)

Iva Holmerová
Chairperson
(Czech Republic)

Charles Scerri
Vice-Chairperson
(Malta)

Jim Pearson
Honorary Secretary
(United Kingdom – Scotland)

Marco Blom
Honorary Treasurer
(Netherlands)

Chris Roberts
Chairperson of EWGPWD
(United Kingdom - Wales)

Stefanie Becker
(Switzerland)

René Friederici
(Luxembourg)

Sabine Jansen
(Germany)

Pat McLoughlin
(Ireland)

Sirpa Pietikäinen
(Finland)

Karin Westerlund
(Sweden)

Maria do Rosário Zincke dos Reis
(Portugal)
Alzheimer Europe staff

Alzheimer Europe staff members in 2020

Jean Georges
Executive Director

Christophe Bintener
Project Officer

Cindy Birck
Project Officer

Kate Boor Ellis
Communications Officer

Angela Bradshaw,
Project Officer

Gwladys Guillory
Event and Conference Coordinator

Dianne Gove
Director for Projects

Owen Miller
Policy Officer

Stefanie Peulen,
Finance Officer

Ana Diaz
Project Officer

Grazia Tomasini
Administrative Assistant

Aileen O’Brien
Administrative Assistant
(left June 2020)
Our members are helping people with dementia and their carers in 33 countries.